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Microglia cells are the resident brain macrophages regulating in the initiation and maintenance of 
neuroinflammation. Chronic or exacerbated activation of microglia can contribute to neurodegenerative 
diseases. In the present thesis, mechanism of endogenous corticosteroids and xenobiotics on microglia 
function were investigated using the mouse BV-2 microlgia cell line. 
 
Corticosteroids are potent modulators of inflammation and mediate their effects by binding to 
mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). MR and GR are suggested to 
regulate microglia activation and suppression, respectively. We showed that GR and MR differentially 
regulate on nuclear factor kappaB (NF-κB) activation and neuroinflammatory parameters, including 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1), converting inactive 11-dehydrocorticosterone to active corticosterone, is involved in the 
action of GR and MR. Both 11-dehydrocorticosterone and corticosterone showed biphasic effects with 
low/moderate concentrations potentiating IL-6 and TNF-α expression and NF-κB activation through 
MR. At high concentrations, corticosteroids suppressed these mediators through GR. We also showed 
that the silane AB110873, indentified by a MR pharmacophore, stimulates mitochondrial reactive 
oxygen species (ROS) generation and the production of the IL-6 by activating MR. 
 
Metabotropic glutamate receptor 5 (mGluR5) has been documented to modulate microglia function. 
Microglial activation induced by (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), a mGluR5 agonist, 
has been shown to decrease microglia activation and release of associated pro-inflammatory factors. 
Additionally, oxidative stress and inflammatory response of microglia cells are associated with AMP-
dependent protein kinase (AMPK) and calcium-mediated signaling. Here, we investigated the 
relationship between oxidative stress and inflammation and AMPK and calcium-mediated pathways in 
the antagonism of mGluR5 with 2-methyl-6-(phenylethynyl)-pyridine (MPEP). MPEP significantly 
increased oxidative stress parameters and inflammatory mediators in a concentration-dependent manner. 
MPEP reduced ATP production and changed the phosphorylation state of AMPK. MPEP increased the 




]i) from endoplasmic reticulum (ER) through IP3 receptor. ER 
stress markers were induced by MPEP and blocked by a chemical chaperone (4-phenyl butyric acid, 4-
PBA) and a calcium chelator (BAPTA-AM). AMPK activation abolished and inhibition potentiated ER 
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stress induced by MPEP. The effect of MPEP on phospholipase C (PLC)-associated pathways was also 
investigated. A PLC inhibitor (U73122), and a Gi protein inhibitor (pertussis toxin, PTX) blocked 
MPEP-induced increase of [Ca
2+
]i. MPEP also significantly increased PLC activity. Furthermore, 
AICAR, BAPTA-AM, U73122, and PTX prevented oxidative stress and inflammatory response induced 
by MPEP. 
 
Excessive and chronic exposure to organotin compounds has been associated with neurotoxicity and 
neuroinflammation. Dibutyltin (DBT) is an organotin widely used as a stabilizer in polyvinyl chloride 
plastics. In the present study, we found that DBT promotes mitochondrial oxidative stress and induces 
ATP depletion, leading to AMPK activation in a time-dependent manner. DBT induced concentration-
dependent increases in IL-6, NADPH oxidase-2 (NOX-2), TNF- expression. NOX-2 inhibitor, 
apocynin inhibited the action of DBT, not only on IL-6 up-regulation but also an intracellular ROS 
production. DBT induced the nuclear translocation of NF-B and NF-B inhibitor Cay10512 blocked 
IL-6 expression induced by DBT. Furthermore, we showed a role for phosphatidylinositol 3-kinase 
(PI3K)/ protein kinase B (Akt), extracellular signal-regulated protein kinase1/2 (ERK1/2), p38 mitogen-
activated protein kinase (p38 MAPK), c-Jun NH(2)-terminal kinase (JNK), protein kinase C (PKC), 
PLC, and [Ca
2+
]i in the DBT-mediated toxicity. 
Trimethyltin (TMT) is an organotin with potent neurotoxic effects, characterized by neuronal 
destruction and neuroinflammation, which involves microglia activation as a consequence of neuronal 
damaged. In the present study, we found that TMT induces the expression of IL-6 and inducible nitric 
oxide synthase (iNOS). Cay10512 blocked TMT-induced translocation of NF-B into nucleus. 
PD98059 and SB20190, inhibitors of ERK1/2 and p38 MAPK, respectively, inhibited the ability of 
TMT to induce IL-6 and iNOS expression. The proinflammatory action of TMT was substantially 
enhanced by low/moderate corticosterone and 11-dehydrocorticosterone but suppressed by 
dexamethasone. Spironolactone suppressed the effects of TMT and the potentiation by corticosterone on 
proinflammatory mediator expression. Similarly, the potentiation of corticosterone was inhibited by 
PD98059 and SB20190.  
 
In conclusion, a tightly coordinated activity of GR and MR regulates the NF-κB pathway and the 
control of inflammatory mediators in microglia cells. The balance of GR and MR activity is locally 
modulated by the action of 11β-HSD1, which is upregulated by pro-inflammatory mediators. This study 
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highlights the role of mGluR5 antagonism in mediating oxidative stress, ER stress and inflammation in 
microglial cells. The calcium dependent pathways are mediated through Gi protein-coupled receptors, 
PLC, and PI3 receptors. AMPK also may play a role in the regulation of mGluR5 by disturbing the 
energy balance. TMT and corticosterone influence the same signaling pathways to exert inflammatory 







Microglia are CNS resident macrophage-like cells that have been implicated as possible contributors to 
neuroinflammation in the brain. These cells become readily activated in response to a wide variety of 
stimuli, such as injuries, axotomy, and inflammation (1). Microglia play an important role in both innate 
and adaptive immune responses in the brain (2). The number of microglia cells represents the increasing 
response to CNS insults such as restraint induced chronic stress in mice (3). The activated microglia 
work to restore homeostasis and are characterized by proliferation and morphological change from the 
ramified resting state to the motile amoeboid morphology that is accompanied by an increase in 
production of pro-inflammatory cytokines (4). The rapid up-regulation of pro-inflammatory products 
aids in the defense against the immune challenge but also potentially contributes to neurological damage 
under conditions of chronic inflammation.  
Increasing evidence suggests that inflammation involving microglia activation through the release of 
pro-inflammatory mediators underlies many neurodegenerative diseases such as Parkinson’s disease 
(PD), Alzheimer disease (AD) and multiple sclerosis (MS) (5-8). The expression of proinflammatory 
cytokines in the pathogenesis of various neurodegenerative diseases has been demonstrated (9-13). 
Proinflammatory cytokines released from microglia such as interleukin-6 (IL-6), interleukin-1 (IL-1β), 
and tumor necrosis factor- (TNF-) play critical roles in microglia-mediated neurodegeneration (14-
16). Moreover, an inflammatory response in the injured brain also elicits pro-inflammatory cytokines 
(17,18). In addition to cytokines, nitric oxide (NO), produced by inducible nitric oxide synthase (iNOS) 
in microglia, is one of the characterized pro-inflammatory factors that induces neuronal death (19-21). 
Moreover, glucocorticoid-induced TNFR family related gene (GITR) was also suggested to play a role 
in the inflammatory response in microglia cells which contribute to inflammatory diseases (22-25). 
Tumor necrosis receptor2 (TNFR2) is highly expressed on microglia cells and plays an important role in 
the regulation of innate immune response following brain injury on infection (26). 
In the CNS, glucocorticoids including corticosterone in the case of rodents or cortisol in humans have 
profound effects on brain development and adult CNS function. Excess or insufficient glucocorticoids 
cause abnormalities in neuronal and glial structure and function. In mammals, the mechanisms for 
responding to stress are regulated by the hypothalamic–pituitary-adrenal (HPA) axis, which results in 
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the releases of glucocorticoids. Glucocorticoids at basal levels have been shown to increase synaptic 
plasticity, and facilitate the maintenance of hippocampus-dependent cognition. In terms of 
neuroinflammation, however, the effects of glucocorticoids in the brain are controversial. Some studies 
showed that glucocorticoids caused an increase in the number of inflammatory cells, such as 
granulocytes, monocytes/macrophages, and microglia in the hippocampus (27,28). While synthetic 
glucocorticoids have long been used as an anti-inflammatory therapy when administered after injury, 
there is increasing evidence that glucocorticoids, a major hormone released during periods of stress, acts 
as a priming event resulting in potentiation of both central and peripheral proinflammatory cytokine 
production following a subsequent systemic immune challenge (29,30). In particular, glucocorticoids 
potentiated the expression of proinflammatory cytokines in cultured neurons (31), suggested that 
glucocorticoids may have a proinflammatory role (29). It has been demonstrated that the administration 
of a single dose of corticosterone that leads to blood levels similar to those observed during an acute 
stressor potentiates the proinflammatory cytokine response to a subsequent systemic inflammatory 
challenge (32). Prior exposure to glucocorticoids potentiated the lipopolysaccharide (LPS)-induced 
production of the pro-inflammatory cytokines IL-1 and IL-6 in spinal neuroinflammation and 
enhanced LPS-induced fever and sickness behaviors in rats (33). Stress-induced glucocorticoids 
function to sensitize the microglial proinflammatory response in the hippocampus to immunologic 
challenges (34). Acute and chronic stress has been found to sensitize or prime the neuroinflammatory 
response to immunologic challenges (28,35). 
At the cellular level, the effects of glucocorticoids are largely a consequence of their transcriptional 
effects mediated via binding to Type I mineralocorticoid receptors (MR) and Type II GC receptors (GR) 
which are members of nuclear receptors. The MR has a higher affinity for corticosterone (Kd, 0.5 nM) 
than does GR (Kd, 2.5–5 nM) (36). In vitro binding studies indicated that naturally produced steroid 
hormones such as corticosterone and cortisol preferentially bind to MR as compared to synthetic 
glucocorticoids like dexamethasone, which showed higher affinity for GR (37). These results were 
confirmed by experiments performed with hippocampal tissue indicating that the MR exhibits increased 
binding with ten-fold higher affinity for endogenous glucocorticoids than GR (38). The high affinity of 
MR for glucocorticoids suggests that at basal levels the MR is mostly occupied whereas the GR is only 
partially bound by glucocorticoids (38). This results in continuous activation of MR at most times, even 
in between bursts of hormone secretion. The GR, however, has a lower affinity for the hormone and 
appears to be primarily activated during times of stress and circadian rhythm induced elevations of 
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corticosteroid concentrations (39). Differential binding by the two receptors in the brain plays an 
important role in the various effects of glucocorticoids observed in the CNS (40).  
Both MR and GR have been identified in cell types that are responsible for the regulation of 
inflammatory responses including dendritic cells, macrophage, lymphocytes, and microglia cells (41). 
The MR is highly enriched in granule cells of the dentate gyrus and in the pyramidal cells of the 
hippocampal CA1 and CA2 regions and to a lesser extent in the hypothalamus, cerebellum, and 
brainstem (42). The GR is more widely distributed throughout the brain than the MR, and it is strongly 
expressed in the hippocampal formation and certain hypothalamic nuclei (43). The GR density is 
highest in the paraventricular nucleus and structures of the limbic system, making it readily accessible 
to the actions of the HPA axis (44). The limbic structures also express a significant amount of MR and 
there are a number of regions, especially the hippocampus, that show co-expression of MR and GR, 
which can be seen across many species (45). 
In addition to the direct effects of corticosteroids on neuronal cells, corticosteroids may modulate brain 
functions through their actions on astrocytes, oligodendrocytes, and microglia because these glial cells 
express GR and MR (43). GR and MR are expressed ex vivo in microglia and GR is the most abundant 
steroid hormone receptor transcript ex vivo in microglia. These receptors have been suggested to 
regulate inflammatory response in microglia cells (41). MR expressed on microglia might play a role in 
the activation of microglia activity (46). Spironolactone, an MR antagonist, inhibited production of 
several pro-inflammatory cytokines via MR mechanisms and showed positive effects in patients with 
inflammatory diseases (47-49). Microglia activation induced by corticosterone and aldosterone was 
decreased by spironolactone (50). However, GR expressed in microglia cells showed suppressive 
effects. The inhibitory effect of corticosterone on proliferation of microglia cells is mediated by GR, but 
not MR (51). In mice, microglial GR protected dopaminergic neurons after acute 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) intoxication and microglial GR gene inactivation exacerbated both 
microglial and astroglia reactivity after acute MPTP treatment (52). Both MR and GR differentially 
regulate the function of mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-
κB) (53-56).  
For the functions of microglia, several studies demonstrated that corticosterone inhibits microglia cells, 
reducing inflammatory reactions in the brain (57,58). Microglia activation induced by acute stress was 
reversed by corticosterone administration (59). Triamcinolone inhibited microglia activation and 
protected neuronal cells from death induced by microglia activation (60). Glucocorticoids inhibited 
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proliferation of microglia cells (61). In vivo experiments have shown that glucocorticoid injection alters 
the density and morphology of microglia cells in immature rats (62). Low concentrations of 
corticosterone decreased the expression of the proinflammatory cytokines IL-1 and TNF- in the rat 
hippocampus following kainic acid stimulus (31), while chronic administration of corticosterone 
increased the level of LPS-induced NF-B activity in the hippocampus of stressed rats (28).   
The local glucocorticoid bioavailability is regulated by intracellular metabolism by 11β-hydroxysteroid 
dehydrogenases (11β-HSDs), which alter the exposure of glucocorticoid receptors to their ligands. 11β-
HSD1 regenerates active glucocorticoids from their inactive 11-keto derivatives and is widely expressed 
throughout the adult CNS (63). Elevated hippocampal and neocortical 11β-HSD1 is observed with 
ageing and causes cognitive decline; its deficiency prevents the emergence of cognitive defects with age 
(64). Microglia also express functional 11β-HSD1 which is suggest to control proinflammatory 
mediator production and inflammation, (65). 
Metabotropic glutamate receptors (mGluRs) are expressed in many different cell types throughout the 
brain and spinal cord (66). Recently, mGluRs have been considered to be promising targets for neuro-
protective agents in both acute and chronic neurodegenerative disorders (67,68). mGluRs are G-protein-
coupled receptors of which there are eight subtypes divided into three groups (I–III) based on their 
sequence homology, signal transduction pathways and pharmacological profiles (67,69). Metabotropic 
glutamate receptor subtype 5 (mGluR5) belongs to the group I receptors, which are typically 
postsynaptic and mediate their signaling through Gαq-proteins. This results in the stimulation of 
phospholipase C (PLC), leading to phosphoinositide hydrolysis and intracellular Ca
2+
 mobilization and 
also activation of extracellular signal-regulated protein kinases (ERK1/2) downstream signaling 
pathways (67). mGluR5 is expressed in microglia (66,70) and the mGluR5 specific agonist (R,S)-2-
chloro-5-hydroxyphenylglycine (CHPG) inhibits microglia activation, oxidative stress, and the release 
of inflammatory mediators both in vitro and in vivo (71-76). Moreover, mGluR5 activation reduced 
fibrinogen-induced microglia activation, which resulted in neuronal protection (77). mGluR5 activation 
reduced β-amyloid-induced cell death in primary neuronal cultures (78). It has been reported that 
mGluR5 is significantly expressed in activated microglia which surround the site of injury following 
traumatic brain injury in rats. This observation may support the idea that pharmacological manipulation 
of the mGluR5 may be beneficial in neuroinflammatory diseases (79,80). The use of mGluR5 agonists 
as a therapy for chronically injured spinal cord has been proposed (68). Therefore, the dysregulation of 
mGluR5 may result in initiation or progression of neurodegenerative disorders. 
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Among the transcription factors that activate the inflammatory genes, NF-κB is perhaps the most 
relevant in microglia cells. Activation of NF-κB is triggered by phosphorylation, which subsequently 
leads to the translocation of the free NF-κB into the nucleus where it promotes the expression of 
proinflammatory genes (81,82). NF-κB transcription is activated by various kinases as well as reactive 
oxygen species (ROS) (83). Phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (Akt) are also 
known to regulate the expression of inflammatory mediators in microglia (82,84,85). MAPKs, including 
p38 MAPK, ERK1/2, and c-Jun NH(2)-terminal kinase (JNK) have been suggested to be critical 
regulators of oxidative stress and proinflammatory signaling cascades (86). Several reports have shown 
that NF-κB, PI3K/Akt, and MAPKs are regulated by intracellular calcium levels and consequently 
influence cytokine expression and release in inflammation responsive-cells (87-93). In addition, it has 
been shown that activation of MAPKs or NF-κB is mediated via the activation of PLC and stimulation 
of protein kinase C (PKC) in various cell types (89,94,95). 
In addition to microglial inflammatory response, accumulating evidence also supports the concept that 
oxidative imbalance and subsequent oxidative stress play an important role in the pathophysiology of 
neurodegenerative diseases (96). Under physiological conditions, cellular redox balance is maintained 
by the equilibrium between the formation and elimination of free radicals such as ROS and NO. 
Excessive generation of ROS/NO or inadequate antioxidant defense can result in damage to cellular 
structures. The CNS appears to be especially vulnerable to oxidative stress due to its high rate of oxygen 
consumption, low levels of molecular antioxidants and the susceptibility of neurons or oligodendrocytes 
due to their specific metabolic properties. ROS have been recognized as an activator to the chronic 
progression of neurodegenerative diseases (8,97,98). ROS plays a key role in microglial response in 
neurodegeneration (99-102). Microglial intracellular ROS generation facilitates pro-inflammatory 
pathways by activating MAPKs and NF-κB signaling (103-106). The NADPH oxidase (NOX) family is 
a series of enzymes involved in producing ROS. NOX-2 is highly expressed in innate immune cells 
including microglia cells. NOX-2 has been implicated in persistent microglial activation, ROS 
formation, and neurodegeneration in substantia nigra (14). iNOS expression plays a prominent role in 
the mechanism of oxidative stress in various cell types.NF-κB, MAPKs, and Janus kinase (JAK)/STAT-
dependent signal transduction play an important role in iNOS expression. mGluR5 modulates cellular 
oxidative status by affecting ROS and NO production through inhibition of NOX-2 activity (71,74-76).  
The CNS strongly depends on efficient mitochondrial function, because the brain has a high energy 
demand. Defects in mitochondrial dynamics, generation of ROS, and environmental factors especially 
oxidative stress may have an influence on energy metabolism and contribute to the pathogenesis of 
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several neurodegenerative diseases (107,108). The mitochondria generate ATP through oxidative 
phosphorylation. Under conditions of low ATP levels, the cellular energy sensor AMP-dependent 
protein kinase (AMPK) positively regulates signaling pathways which replenish ATP (109-111). 
Alternatively, AMPK is directly targeted and activated by pro-oxidant species or intracellular calcium 
levels (112,113). Although AMPK is considered to be a pro-survival kinase, it has been reported that 
prolong activation can induce cell damage including endoplasmic reticulum (ER) stress (113-116). 
AMPK can also interact with the MAPK signaling cascade to mediate apoptosis, a process elicited by 
both energetic imbalance and pro-oxidant conditions, such as treatment with H2O2 or UV (117).  
The energy balance also influences oxidative stress and inflammatory responses in microglia, which 
contributes to disease progession (118-121). AMPK has been suggested to play a role in the regulation 
of metabolic homeostasis and cytokine release (122,123). Once activated, AMPK, in parallel, decreases 
ATP consuming pathways whilst activating pathways to enhance ATP production. If conditions are 
particularly stressful, AMPK affects cell viability by activating apoptosis and/or autophagy. AMPK was 
commonly recognized as a pivotal sensor of cellular energy balance. Disturbance of the AMPK pathway 




 levels have been implicated to regulate several activities of microglia including 
cytokine release, migration, ROS generation, and proliferation (128-131). Calcium also serves as the 
key link coupling cellular energy balance and mitochondrial ATP production. Mitochondrial calcium 
uptake is associated with an increase in mitochondrial bioenergetics and inflammatory response. 
However, a consequence of mitochondrial calcium uptake is the production of ROS, which plays a 





]i) are increased either by the release of Ca
2+
 from the ER or by entry across the plasma 
membrane (132,133). The ER also serves as a Ca
2+
 reservoir regulated by two major Ca
2+
 release 
channels, the 1,4,5-trisphosphate receptor (IP3R) (134,135) and the ryanodine receptor (RyR) (135), as 
well as by Ca
2+
 ATPases, which control Ca
2+
 transport into the ER (135). The prolong depletion of Ca
2+
 
in the ER and Ca
2+
 overload in the cytoplasm are main causes of ER stress (136,137). ER stress is 
generally caused by an overload of unfolded proteins in the ER, which activates the unfolded protein 
response (UPR), involving the transcriptional up-regulation of ER-chaperones, attenuation of protein 
translation and ER-associated degradation of misfolded proteins (137,138). Inositol-requiring enzyme-1 
(IRE1), activating transcription factor 6 (ATF6), and PKR-like ER kinase (PERK) act as transducers in 
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the UPR signaling pathway. The ER-resident molecular chaperones including glucose-regulated protein 
78 (GRP78) and glucose-regulated protein 94 (GRP94) as well as the transcriptional factor C/EBP 
homologous protein (CHOP) are induced by the UPR and they increase ER protein-folding capacity and 
maintain storage of ER Ca
2+
 (138,139). In addition, perturbation of ER integrity and increased ROS 
production are induced by an accumulation misfolded proteins in the ER, leading to the activation of the 
UPR (140). Prolonged ER stress results in cell death by the apoptotic pathway mediated by caspase-12, 
an ER localized cysteine protease (138). In addition to calcium homeostasis, impairment of 
mitochondrial function and AMPK signaling have been considered to modulate the ER stress response 
(117,141-145). Specifically, mitochondrial dysfunction activated AMPK, leading to ER stress through 
NO production, resulting in apoptosis of pancreatic β-cells (143). Activation of AMPK resulted in ER 
stress in several cell types (117,142,145). Conversely, AMPK activation by AICAR attenuated ER 
stress and protected SH-SY5Y neuroblastoma cells against homocysteine-induced neurotoxicity (141). 
The elevation of intracellular calcium is mediated by PLC-mediated IP3 formation, which is a well-
established downstream signaling effector of G protein-coupled receptor (GPCR) activation. 
Stimulation of GPCRs activates the Gq protein, promoting its dissociation into Gqα and Gβγ Gβγ and 
the exchange of guanosine diphosphate bound to Gαq for GTP. The resulting GTP-Gαq complex 
activates the β isoforms of PLC (146). mGluR5 activation in microglia has been suggested to be 
involved in the Gαq-protein signal transduction pathway through PLC, PKC and Ca2+ (72). However, 
pertussis toxin (PTX)–sensitive Gi proteins and IP3 signaling resulting in [Ca
2+
]i increase has been 
reported (147-150). Taken together, the evidence suggests that not only Gq-coupled receptors but also 
Gi-coupled receptors can contribute to increase [Ca
2+
]i by release from the ER. In addition, many 
reports indicate that the synthesis of IP3 and [Ca
2+
]i signaling by one type of G-protein–coupled receptor 
can be influenced by the stimulation of a different type of GPCR (151-153). 
In the past several decades, organotins have been widely used as polyvinyl chloride (PVC) stabilizers, 
industrial catalysts, agricultural biocides, wood preservatives, and antifouling agents in paints (154). 
The major sources of organotin intake for humans are dietary sources, such as seafood and shellfish, 
food crops, and drinking water. A serious problem is that organotins can accumulate in fish, animals 
and plants (155), exposing humans who are in further up in the food chain, to these substances (156). 
Most organotins have been reported to be toxic in humans (157). Several animal experiments have 
suggested that the spectrum of potential adverse chronic systemic effects of organotins in humans is 
quite broad including immune suppression, endocrine disruption, neurotoxicity, and metabolic toxicity. 
Organotins affect many organs and disrupt multiple physiological functions causing reproductive 
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disturbance, teratogenicity, developmental disorders, and possibly carcinogenicity (158,159). Therefore, 
there is an increasing concern that their widespread use may cause adverse effects within environmental 
and biological systems. 
Organotin compounds are characterized by a tetravalent structure with at least one carbon–tin bond, and 
they are classified as mono-, di-, tri- and tetra-alkyltins, depending on the number of added alkyl groups 
(Figure1). Triorganotins including tributyltin, triphenyltin, and trimethyltin possess a high specificity of 
action and are cytotoxic in several test systems (158,160,161). Particularly, studies on the toxicity of 
triorganotins, especially trimethyltin (TMT), have been mainly focused on neurotoxicity. TMT 
intoxication in animals exhibited a variety of adverse effects on the CNS including seizures, self-
mutilation, vocalization, hyperactivity and aggressive behavior, because of extensive neuronal damage 
(162,163). Accidental human exposure to TMT has resulted in similar adversities including weakness, 
aggressive behavior, depression, disorientation, seizures, severe memory loss and death in severe cases 
(164). Due to their high toxicity, triorganotins have been banned for industrial or agricultural 
applications. However, dialkyltins are still widely used. 
TMT has been known as a classic neurotoxicant. TMT can accumulate in the body and pose a risk for 
workers chronically exposed to a low dose of TMT. Neurobehavioral changes were observed in rats and 
mice treated with TMT (165). TMT induced neurotoxicity by interfering with synaptic and 
neurodegeneration-related networks and protein processing and degradation pathway (166). One of the 
proposed mechanisms for the neurotoxicity of TMT is the induction of inflammation. Memory 
dysfunction induced by TMT in rats was observed with up-regulation of the mRNA expression levels of 
reactive microglia marker and proinflammatory cytokines (167). The inflammatory responses by 
increasing cytokine expression after TMT treatment in adipocytes were reported (168). In addition, in 
vitro experiments, TMT-induced apoptosis in human neuroblastoma cells through activation of NF-κB, 
JNK, ERK, and p38 was observed (169). Although the potential neurotoxicity of TMT has been widely 
reported, the critical target molecules for the mechanisms of induction of inflammation in microglia 
remain unclear. 
Many reports exhibited a significant involvement of endogenous corticosterone in the pathological 
phenomena related to TMT toxicity. Particularly, the plasma corticosterone concentration transiently 
increased in TMT-treated rats (170) together with alterations of neuropathological and behavioral 
features (171) and induced hippocampal necrosis (172). Time-and concentration-dependent changes of 
plasma corticosterone after TMT injection were also observed in mice (173). Both endogenous and 
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exogenous glucocorticoids prevented neuronal degeneration induced by TMT in mouse brain (174). In 
addition, TMT cytotoxicity seems to be oppositely regulated by GR and MR activity. Spironolactone 
protected neurons in dentate granule cells from TMT cytotoxicity whereas, the GR antagonist 
mifepristone potentiated the TMT cytotoxicity (173). However, the role of corticosterone in TMT-
induced inflammation is still unclear whether it acts as a protective or deleterious factor and it needs to 
be determined. 
Dibutyltin (DBT) is found in the environment and in dietary sources (175-177). DBT is used as biocide 
or as stabilizer in a wide range of industrial and agricultural applications (178). DBT has been detected 
in drinking water supplied via PVC pipes (179). Importantly, DBT is a degradation product of 
tributyltin (TBT), which has been used as a fungicide, wood preservative, and antifoulant (180). In 
human tissues, DBT was detected in human liver (181-183). Concentrations of DBT in the range of 3–
100 nM were observed (184,185). DBT is found in human blood at concentrations ranging as high as 
300 nM (184,186). TBT shows toxicity in various cell types including; neurons (187-189), hepatocytes 
(190,191), T-lymphocytes (192) and osteoblasts (193). A number of studies suggested that DBT may be 
neurotoxic. For example, DBT has proven as a developmental neurotoxicant in vitro and in vivo (194). 
DBT significantly inhibited neurite outgrowth and was found to be even more toxic than TMT in vitro 
(195). In primary cultures of cerebellar granule cells, DBT showed potent neurotoxicity through 
induction of apoptosis (179). DBT neurotoxicity in aggregating brain cell cultures affected the myelin 
content in cholinergic neurons. In addition, markers for astrocytes and oligodendrocytes were 
diminished (195). DBT at concentrations of 0.25-100 M caused a decrease in cell viability, 
mitochondrial potential and cell proliferation in neuroblastoma cells (196). DBT significantly inhibited 
neurite outgrowth and caused cell apoptosis in PC12 cells (197). Developmental neurotoxicity of DBT 
and the distribution of total tin (Sn) in the brain after DBT exposure was documented (198). DBT was 
consistently present in the brain in a two-generation reproductive toxicity study of TBT (183). In 
addition, DBT caused in vivo neurotoxicity with increasing apoptotic cell death in the neocortex and 
hippocampus of offspring (194). DBT interfered with the secretion of TNF- in natural killer cells and 
the effects were concentration dependent (199). 
However, the neuroinflammatory action of DBT is still not well investigated. Several studies explored 
the inflammatory responses following DBT exposure in in vitro and in vivo. In human natural killer 
cells, several transcription factors were induced by DBT, mediated by MAPKs (200,201). Necrosis 
induced by DBT was observed in T-lymphocytes contributing the thymic atrophy in rats (192). 
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Although DBT toxicity in the nervous system has been extensively studies, the focus was mainly on 
neuronal cells.  
BV-2 microglia cells have been successfully used to study functions of microglia including 
inflammatory responses, oxidative stress, ER stress, and intracellular regulation triggered by toxic 
compounds (162,202,203). In the present studies, we used BV-2 cells as a model to investigate the 
effects of glucocorticoids and xenobiotic compounds such as organotins on the inflammatory mediators 
and oxidative stress at the cellular and molecular levels. The effects of the endogenous glucocorticoids 
11-dehydrocorticosterone and corticosterone, the mineralocorticoid aldosterone and the synthetic 
glucocorticoid dexamethasone on NF-κB activation and IL-6 expression in the presence or absence of 
MR and GR antagonists were investigated. Further, the impact of proinflammatory cytokines and 
corticosteroids on the expression of TNFR2 and 11β-HSD1 was studied. The direct effect of mGluR5 
inhibition on [Ca
2+
]i and the receptors involved were tested. The key signaling pathways of increased 
calcium including oxidative stress, mitochondrial function, the release of proinflammatory cytokines, 
and ER stress induced by blockage of mGluR5 were investigated. Moreover, the action of the 
xenobiotics, silane AB110873 which has MR agonist properties, on the induction of IL-6 release and 
oxidative stress was elucidated. The effects of DBT on AMPK, NF-κB, PI3K/Akt, MAPKs, Ca2+, PLC, 
and PKC contributing to oxidative stress and cytokine release were investigated. Furthermore, the role 
of NF-κB and MAPKs and their influence on the TMT-mediated induction of iNOS and/or IL-6 
expression in microglia cells was examined. The role and regulation of glucocorticoids on TMT action 








Figure 1: Structures of organotins. (A) tributyltin (TBT) chloride, (B) dibutyltin (DBT) dichloride, (C) 
monobutyltin (MBT) trichloride, and (D) trimethyltin chloride (TMT) modified from (196). 
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Hypotheses and aims 
Microglia are implicated in the pathogenesis of neuroinflammatory conditions such as Alzheimer 
disease, Parkinson disease, and multiple sclerosis. Therefore, factors influencing microglia functions 
may contribute to the development of diseases. In order to better understand the mechanisms of 
endogenous corticosteroids and xenobiotic compounds on microglia activation, further research is 
needed. Therefore, in this thesis addressed the following hypotheses and tasks: 
1. The balance of local corticosteroids regulated by 11-HSD1 and its regulation by signaling pathways 
such as NF-B and MAPKs in microglia is yet to be fully understood. Glucocorticoids impacts on 
microglia inflammatory activity and the exact mechanism need to be uncovered. 
2. The metabotropic glutamate receptors (mGluRs) modulate microglia function through inhibition of 
intracellular calcium regulation. 
3. Xenobiotic compounds disturb microglia functions by induction of oxidative stress, ER stress, and 
inflammatory responses. 
4. Xenobiotic compounds disturb glucocorticoid functions in microglia resulting in enhanced 
microglia activity and susceptibility. 
More specifically the aims were to: 
1. Characterize if glucocorticoids alter the inflammatory responses of microglia cells  
2. Characterize if xenobiotic compounds alter microglia functions including inflammatory response, 
oxidative stress, and ER stress. 
3. Elucidate the involvement of metabotropic glutamate receptors and intracellular calcium on 
microglia functions 
4. Elucidate the importance of NF-B, MAPKs, AMPK, and PI3K/Akt pathways in microglia cells 
during exposure to xenobiotic compounds and/or glucocorticoids. 
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Real-time PCR primers 
Genes Primers Sequences 
GAPDH (mouse) forward  CTCGTGGAGTCTACTGGTGT 
reverse GTCATCATACTTGGCAGGTT 
IL-6 (mouse) forward  GGAGGCTTAATTACACATGTT 
reverse TGATTTCAAGATGAATTGGAT 
TNF- (mouse) forward  TTCTGTCTACTGAACTTCGG 
reverse GTATGAGATAGCAAATCGGC 
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Background: Metabotropic glutamate receptor 5 (mGluR5) activation by (RS)-2-chloro-5-
hydroxyphenylglycine (CHPG) decreases microglial activation and the release of associated pro-
inflammatory factors in vitro and in vivo. AMP-dependent protein kinase (AMPK) and calcium 
mediated signaling are associated with oxidative stress and inflammation in microglia cells. Here we 
examined whether mGluR5 antagonism by 2-methyl-6-(phenylethynyl)-pyridine (MPEP) enhances 
oxidative stress and inflammation through AMPK and Ca
2+
 mediated signaling pathways in mouse BV-
2 microglia cells.  
Methods: Dihydroethidium (DHE), MitoTracker
®
Red CMXRos, and MitoSOX Red was used to assay 
intracellular ROS production, mitochondrial mass, and mitochondrial ROS production, respectively. 
mRNA expression of interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) glucose-regulated 
protein 78 (GRP78), glucose-regulated protein 94 (GRP94), and transcriptional factor C/EBP 
homologous protein (CHOP) was assessed by real-time PCR. Protein expression of IL-6, cellular ATP-
content, and phospholipase C activity were measured by ELISA, luminescent, and fluorescent assay, 




]i) was determined by Fuo-4 fluorescent in 
calcium free medium. The AMPK activity was determined by Western analysis of AMPK 
phosphorytion. 
Results: MPEP significantly increased oxidative stress parameters in a concentration dependent manner 
following MPEP exposure including, intracellular ROS levels, mitochondrial ROS levels, mitochondrial 
mass, and iNOS. Concentration and time-dependent activation of the inflammatory response with 
increasing IL-6 mRNA expression and secretion was observed. MPEP (100 M) reduced ATP 
production and changed the phosphorylation state of AMPK. MPEP increased levels of [Ca
2+
]i in a 





]i) induced by MPEP. In addition, MPEP had no effect on the thapsigargin 
92 
induced elevation of [Ca
2+
]i rise. These results suggest that the [Ca
2+
]i  pool originated from the ER. 
Pretreatment of the cells with xestospongin C, an inhibitor of the IP3 receptor, blocked the action of 
MPEP on [Ca
2+
]i. ER stress markers including, CHOP, GRP78, and GRP96 were induced by MPEP and 
were blocked by 4-phenyl butyric acid (1 mM) and BAPTA-AM (1 M). Pretreatment of the cells with 
AICAR (1 mM) partially abolished ER stress induced by MPEP. Pretreatment of the cells with 
compound C (1 M) potentiated ER stress induced by MPEP. U73122 (5 M), a PLC inhibitor, and 
pertussis toxin (PTX; 100 ng/ml), a Gi protein inhibitor blocked MPEP induced [Ca
2+
]i . MPEP (100 
M) also significantly increased PLC activity. In addition, pretreatment the cells with AICAR, BAPTA-
AM, U73122, and PTX prevented oxidative stress as well as inflammatory response induced by MPEP. 
Conclusions: This study highlights the potential pathophysiological role of mGluR5 antagonism in 
mediating oxidative stress, ER stress and inflammation through both Ca
2+
 dependent and independent 
pathways in microglial cells. The Ca
2+
 dependent pathways involve Gi protein-coupled receptors, PLC 
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Neuroinflammation involves, i) an activation and recruitment of immune cells, such as, microglia, 
macrophages, and lymphocytes, and ii) an expression of factors designed to respond to the injury and 
aid in repair. Microglia are resident immune cells in the central nervous system and play an integral role 
in the neuroinflammatory response. Microglia activation is widely implicated as hallmarks in several 
neurodegenerative diseases [1]. Metabotropic glutamate receptors (mGluRs) are expressed in many 
different cell types throughout the brain and spinal cord [2]. Recently, mGluRs have been considered to 
be a promising target for neuroprotective agents in both acute and chronic neurodegenerative disorders 
[3, 4]. mGluRs are G-protein-coupled receptors of which there are eight subtypes divided into three 
groups (I–III) based on their sequence homology, signal transduction pathways and pharmacological 
profiles [3, 5]. Metabotropic glutamate receptor subtype 5 (mGluR5) is a group I member, which are 
typically postsynaptic and mediate their signaling through Gαq-proteins. This results in the stimulation 
of the phospholipase C, leading to phosphoinositide hydrolysis and intracellular Ca
2+
 mobilization and 
also activation of ERK1/2 downstream signaling pathways [3]. mGluR5 is expressed in microglia [2, 6] 
and the mGluR5 specific agonist (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG) inhibits microglia 
activation, oxidative stress, and the release of inflammatory mediators both in vitro and in vivo [7-12]. 
Moreover, mGluR5 activation reduced fibrinogen-induced microglia activation which resulted in 
neuronal protection [13]. mGluR5 activation reduced β-amyloid-induced cell death in primary neuronal 
cultures[14]. It has been reported that mGluR5 is significantly expressed in activated microglia which 
surround the site of injury following traumatic brain injury in rats. This observation may support the 
idea that pharmacological manipulation of the mGluR5 may be beneficial in neuroinflammatory 
diseases [15, 16]. The use of mGluR5 agonists as a therapy for chronically injured spinal cord has been 
purposed [4]. Therefore, the dysregulation of mGluR5 may result in initiation or progression of 
neurodegenerative disorders. 
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Oxidative stress is a common feature of neurodegenerative diseases which increased levels of reactive 
oxygen species (ROS) [17, 18]. Under physiological conditions, cellular redox balance is maintained by 
the equilibrium between the formation and elimination of free radicals such as ROS and nitric oxide 
(NO). Excessive generation of ROS/NO or inadequate antioxidant defenses can result in damage to 
cellular structures. ROS plays a key role in microglial response in neurodegeneration [19-22]. 
Microglial intracellular ROS generation facilitates pro-inflammatory pathways by activating the 
mitogen-activated protein kinases (MAPKs) and NF-κB signaling [23-26]. mGluR5 modulates cellular 
oxidative status by affecting ROS and nitric oxide (NO) production through inhibition of NOX-2 
activity [7, 10-12]. The central nervous system (CNS) strongly depends on efficient mitochondrial 
function, because the brain has a high energy demand. Defects in mitochondrial dynamics, generation of 
ROS, and environmental factors especially oxidative stress may have an influence on energy 
metabolism and contribute to the pathogenesis of several neurodegenerative diseases [27, 28]. The 
mitochondria generates ATP through oxidative phosphorylation. Under condition of low ATP levels the 
cellular energy sensor, AMP-dependent protein kinase (AMPK) positively regulates signaling pathways 
which replenish ATP [29-31]. Alternatively, AMPK is directly targeted and activated by pro-oxidant 
species or intracellular calcium levels [32, 33]. Although AMPK is considered to be a pro-survival 
kinase, it has been reported that prolong activation can induce cell damage including endoplasmic 
reticulum (ER) stress [33-36]. AMPK can also interact with the MAPK signaling cascade to mediate 
apoptosis, a process elicited by both energetic imbalance and pro-oxidant conditions, such as treatment 
with H2O2 or UV [37]. AMPK can also modulate inflammation in muscle cells [38].  
Changes in Ca
2+
 level have been implicated to regulate several activities of microglia including cytokine 
release, migration, ROS generation, and proliferation [39-42]. Calcium also serves as the key link 
coupling cellular energy balance and mitochondrial ATP production. Mitochondrial calcium uptake is 
associated with an increase in mitochondrial bioenergetics and inflammatory response. However, a 
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consequence of mitochondrial calcium uptake is the production of ROS which plays a major role in the 





increased either by the release of Ca
2+
 from ER or by entry across the plasma membrane [43, 44]. The 
ER also serves as a Ca
2+
 reservoir regulated by two major Ca2+ release channels, the 1,4,5-
trisphosphate receptor (IP3R) [45, 46] and the ryanodine receptor (RyR) [46], as well as by Ca
2+
 
ATPases which control Ca
2+
 transport into the ER [46]. The prolong depletion of Ca
2+
 in the ER and 
Ca
2+
 overload in cytoplasm are mainly causes of ER stress [47, 48]. ER stress is generally caused by an 
overload of unfolded proteins in the ER, which activates the unfolded protein response (UPR) which 
consists of the transcriptional up-regulation of ER-chaperones, attenuation of protein translation; and 
ER-associated degradation of misfolded proteins [48, 49]. Inositol-requiring enzyme-1 (IRE1), 
activating transcription factor 6 (ATF6), and PKR-like ER kinase (PERK) act as transducers in the UPR 
signaling pathway. The ER-resident molecular chaperones including glucose-regulated protein 78 
(GRP78) and glucose-regulated protein 94 (GRP94) as well as the transcriptional factor C/EBP 
homologous protein (CHOP) are induced by the UPR and they increase ER protein-folding capacity and 
maintain storage of ER Ca2+ [49, 50]. In addition, perturbation of ER integrity and increased ROS 
production are induced by an accumulation misfolded proteins in the ER, leading to the activation of the 
UPR [51]. Prolonged ER stress results in cell death by the apoptotic pathway mediated by caspase-12, 
an ER localized cysteine protease [49]. In addition to calcium homeostasis, impairment of 
mitochondrial function and AMPK signaling have been considered to modulate the ER stress response 
[37, 52-56]. Specifically, mitochondrial dysfunction activated AMPK, leading to ER stress through NO 
production, resulting in apoptosis of pancreatic β-cells [54]. Activation of AMPK resulted in ER stress 
in several cell types [37, 53, 56]. Conversely, AMPK activation by AICAR attenuated ER stress and 
protected SH-SY5Y neuroblastoma cells against homocysteine-induced neurotoxicity [52]. 
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The elevation in intracellular calcium is mediated by Phospholipase C (PLC)-mediated IP3 formation 
which is a well-established downstream signaling effector of G protein-coupled receptor (GPCR) 
activation. Stimulation of GPCRs activates the Gq protein, promoting its dissociation into Gqα and Gβγ 
Gβγ and the exchange of guanosine diphosphate bound to Gαq for GTP. The resulting GTP-Gαq 
complex activates the β isoforms of PLC [57]. mGluR5 activation in microglia has been suggested to 
involve in the Gαq-protein signal transduction pathway through PLC, PKC and Ca2+ [8]. However, 
pertussis toxin (PTX)–sensitive Gi proteins and IP3 signaling resulting in [Ca
2+
]i increase has been 
reported [58-61]. Taken together, these evidences suggest that not only Gq-coupled receptors but also 
Gi-coupled receptors can contribute to release of [Ca
2+
]i from the ER. In addition, many examples 
indicate that the synthesis of IP3 and [Ca
2+
]i signaling by one type of G-protein–coupled receptor can be 
influenced by the stimulation of a different type of GPCR [62-64]. 
To our knowledge, the direct effect of mGluR5 inhibition on [Ca
2+
]i has not been tested in microglia. 
We showed in this present study that of mGluR5 inhibition resulted in [Ca
2+
]i elevation mainly through 
IP3 receptor activation. The key contributions of increased calcium in microglia cells including 
oxidative stress, mitochondrial function, the releasing of pro-inflammatory cytokines, and ER stress 
were induced by blockage of mGluR5. Furthermore signaling pathways of Gi-coupled receptor, AMPK, 
and PLC-IP3 pathway involved in mGluR5 inhibition. 
Methods 
Materials 
Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 medium, penicillin, streptomycin, 0.05% 
(w/v) trypsin/EDTA, non-essential amino acids (NEAA), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Hank’s balanced salt solution (HBSS), EnzChek Direct 
Phospholipase C Assay kit, Hoechst 33342 dihydroethidium (DHE), Mitotracker Red CMXRos, 
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MitoSOX Red, Furo-4, and probenecid were obtained from Invitrogen (Carlsbad, CA, USA). Fetal 
bovine serum was from Atlanta Biologicals (Lawenceville, GA, US). Cell Titer Glo

 Assay kit was 
purchased from Promega (Madison, WI, USA). Dibutyltin dichloride (DBT), thapsigargin, AICAR, 
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG), 6-methyl-2-(phenylethynyl)-pyridine (MPEP), 
BAPTA-AM, pertussis toxin (PTX), dantolene sodium, and sodium phenylbutyrate (PBA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Compound C and Xestrospongin C were 
obtained from Calbiochem (Sandiego, CA, USA). Specific antibodies against AMPK, and 
phosphorylated form and GRP78 were obtained from Cell Signaling Technology (Danvers, MA, USA). 
Specific antibodies for β-actin and goat anti-rabbit IgG- horseradish peroxidase were obtained from 
Santa Cruz Biotechnology (Santa, CA, USA). 
Cell culture and experimental procedure 
BV-2 murine microglial cells immortalized by infection with v-raf/c-myc recombinant retrovirus [65] 
were kindly provided by Professor Wolfgang Sattler, University of Graz, Graz, Austria. The BV-2 cells 
were propagated in 75 cm
2
 flasks in RPMI 1640 medium plus 10% fetal bovine serum, 2 mM 
glutamine, 100 g/mL streptomycin, and 100U/mL penicillin, HEPES and 0.1 mM NEAA at 37°C, 5% 
CO2. The medium was changed every second day. Cells were sub-cultured at a level of approx. 70-80% 
confluence. Prior to initiating the experiments, cells were re-suspended in culture medium, and cells 
were seeded again to reach confluency of 70% in DMEM supplemented with 10% fetal bovine serum 
1000 mg/L glucose, 2 mM glutamine, 100 g/mL streptomycin, and 100 U/mL penicillin, HEPES, and 
0.1 mM NEAA. Prior to initiating the experiments, cells were cultured in 96-well (1 × 10
3
 cells/well), 
24-well (2 x 10
4
 cells/well), 12-well (0.5 × 10
6
 cells/well) or 6-well (1.0 × 10
6
 cells/well) plates with 
fresh DMEM supplemented with 10% fetal bovine serum 1000 mg/L glucose, 2 mM glutamine, 100 
g/mL streptomycin, and 100 U/mL penicillin, HEPES, and 0.1 mM NEAA. For experimental 
purposes, cells in exponential growth phase (approximately 60–70% confluency) were used. The 
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following cell numbers for seeding were used: 1 × 10
3
 cells/well in 96-well plates for determination of 
total ROS, mitochondrial ROS, mitochondrial mass, IL-6 protein level, total ATP content, and 
intracellular calcium level; 5 × 10
5
 cells/well in 12-well plates for gene expression analysis; 1.0 × 10
6
 
cells/well in 6-well plates for Western blot analysis. 
RNA isolation, reverse-transcriptase (RT) reaction and real-time PCR 
 Isolation of total RNA  
Total RNA was isolated from cultured cells using RNA was isolated using Tri-reagent from Sigma 
Aldrich (St. Louis, MO, USA) according to the manufacturer's instructions with a few modifications, 
and stored at -80
°
C. Briefly, cells from each well of 12-well plate were collected in the presence of 1 ml 
Tri-reagent to disrupt the cells and release the RNA and then 0.2 ml chloroform was added.  After 
vigorous shaking and incubation at room temperature for 30 min, the samples were centrifuged at 
12,000×g for 30 min at 4 °C. The clear upper phase containing the RNA was aspirated. An equal 
volume of cold isopropanol was added and the solution was allowed to stand at room temperature for 
overnight before being centrifuged as mentioned above. The pellet was collected and washed with 1 ml 
cold 75% ethanol followed by centrifugation at 7500×g for 10 min. After the final wash, the ethanol 
was removed and the pellet was air-dried and re-dissolved in DEPC-treated water. Efficiency and 
quality of RNA extraction was measured using 260/280 ratios of optical density from each sample with 
a NanoDrop
®
 Spectrophotometer (NanoDrop Technologies). The 260/280 ratios above 1.8 was accepted 
as pure quality total RNA. 
cDNA synthesis 
Complementary DNA was synthesized from 0.5 g total RNA using Superscript III reverse 
transcriptase (Invitrogen, Carlsbad, CA). The cDNA reaction containing with 0.5 g of total RNA and 
0.5 g of oligo (dT) primers was incubated at 56 C for 5 min and then the reaction mix (containing 
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with 5x first strand buffer, dithiothreitol (DTT), RNAse out inhibitor (50 units), dNTPs , and 
Supersript
®
 Reverse Transcriptase (RT)-III). The reaction was performed at 42 C. After 1 h., DEPC-
treated water was added. The concentration and the purity of the single stand DNA were assessed with a 
NanoDrop
®
 Spectrophotometer (NanoDrop Technologies). Synthesized first strand cDNA samples were 
stored at -20 C until used. 
 RT-PCR assay and data analysis 
Quantitative real-time RT-PCRs were performed using the rotor-gene-3000A (Corbelt Research, 
Australia) in a total reaction volume of 10 l. The reverse-transcriptase (RT) mixture was mixed with 
the KAPA SYBR
®
 FAST qPCR Kit (Kapasystems, Boston, MA) and gene-specific primers. Primers for 
GAPDH, iNOS, IL-6, CHOP, GRP78, and GRP96 were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Thermal cycler parameters were as follows: hold for 15 min at 95C, followed by amplification 
of cDNA for 40 cycles with melting for 15 s at 94C and annealing for 30 s at 56C, and extension for 
30 s at 72C. For each sample, three replicates were analyzed. Expression was normalized to GAPDH. 
Fold changes were quantified as 2
-(ΔCt sample-ΔCt control)
, as described previously [66] The primers for real-
time PCR were listed in Table 1S. 
Preparation of whole cell lysates 
Cells grown in 6-well plates (1.0 × 10
6
 cells/well) were treated with selected compounds for indicated 
times. For making whole cell lysates, the cells were washed twice with ice-cold phosphate-buffered 
saline and harvested in cold RIPA buffer (Sigma-Aldrich, St. Louis, MO) supplemented with 2% 
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The extract was centrifuged at 
10,000 × g for 15 minutes at 4°C in order to remove cell debris.   
Western blot analysis 
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Equal amounts of whole cell protein (30 μg) for each sample were separated by electrophoresis in 10% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, US) at 120 mA for 
1 h. The membranes were blocked for 1 h at 25 °C in Tris-buffered saline, pH 7.4 (TBS) with 0.1% 
Tween 20 (TBS-T) containing 5% non-fat milk. Next, the blots were incubated overnight at 4°C with 
primary antibodies against AMPK(D63G4) (1:1000), phospho-AMPK(Thr172) (1:1000), GRP78 
(1:500), and β-actin (1:2000). All primary antibodies used in this study were purchased from Cell 
Signaling Technology (Danvers, MA). The membranes were washed with TBS-T and then incubated 
with goat anti-rabbit IgG-horseradish (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h at 25 
°C. After washing the membranes with TBS-T, immunolabeling was detected using an enhanced 
chemiluminescence HRP substrate (Millipore, Billerica, MA, US) according to the manufacturer’s 
instructions using a Fujifilm LAS-4000 detection system (Bucher Biotec, Basel, Switzerland). β-actin 
was used for loading control of whole cell protein extracts.   
Measurement of intracellular ROS, and mitochondrial content, mitochondrial ROS by 
ArrayScan
®
 high-content screening system 
Total ROS, mitochondrial mass, and mitochondrial ROS were determined by using the specific 
fluorescent dyes including dihydroethidium (DHE), MitoTracker
®
Red CMXRos, and MitoSOX Red, 
respectively (Invitrogen, Carlsbad, CA, USA). After the treatments, DHE (10 μg/ml), MitoTracker®Red 
CMXRos (200 nM), or MitoSOX Red (5 μM) were added to live cells and incubated for 10, 30, and 20 
min, respectively. Cells were washed with PBS and fixed with 4% formaldehyde for 15 min. Fixed cells 
were permeabilized with 0.1% Triton X-100 in PBS. Nucleus was stained with Hoechst 33342. Stained 
cells were visualized and images were captured and the amount of fluorescent was quantified using 
ArrayScan
®
 high-content screening system (Cellomics Inc, Pittsburgh, PA). Cell health profiling 
bioapplication module was used to quantify the fluorescence intensities of each dye and captured with 
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appropriate filter on 20 fields with each field containing approximately 1000 cells. Cells were identified 
using Hoechst dye and a nuclear mask was generated from images of Hoechst-stained nuclei. The 
intracellular ROS, mitochondrial content, and mitochondrial ROS were reported as the percentage of 
fluorescent intensity compared with control group. 
Phospholipase C activity assay 
Phosphotidylcholine-specific PLC activity was determined in in whole-cell lysates by using the 
EnzChek Direct Phospholipase C Assay (Invitrogen Corporation, Carlsbad, CA, USA). The assay 
measures PLC activity by addition of a proprietary substrate, which is cleaved by phosphotidylcholine-
specific PLC. The cleavage releases the dye-labeled diacylglycerol, which produces a positive 
fluorescence signal that can be measured. Briefly, 100 l cell lysates of treated cells were incubated 
with 100 l substrate working solution (glycerol-phosphoethanolamine with a dye-labeled sn-2acyl 
chain) for 30 min then fluorescence (490 nm excitation and 520 nm emission) was measured by a 
SpectraMax Gemini EM (Molecular Device, Devon, UK). To account for different protein 
concentrations of the samples enzyme activity was normalized to protein concentration of the respective 
cell lysate resulting in mU per µg of protein. 
ATP-content 
Total ATP content was measured by a luminescence-based assay with CellTiter-Glo
®
 Luminescent Cell 
Viability Assay kit following the manufacturer's instruction (Promega, Madison, WI). Briefly, the assay 
buffer and substrate were equilibrated to room temperature, and the buffer was transferred to and gently 
mixed with the substrate to obtain a homogeneous solution. After treatment protocol, 100 µl of the 
assay reagent was added into each well and the content was gently mixed with light protection on an 
orbital shaker to induce cell lysis. After 30 min, the luminescence was quantified on a Microplate 
Reader (SpectraMax GeminiEM, Molecular Devices, Devon, UK). The luminescent signals for the 
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treated cells were normalized to the luminescent signal of cells treated with control group, which was 
arbitrarily set to 100%. 
Protein determination 
Protein concentrations were determined by using a Pierce
®
 BCA protein assay kit (Thermo Scientific, 
US) according to the manufacturer's instructions. Bovine serum albumim was used as a protein 
standard. Absorbance was measured at 595 nm by using a UV-max kinetic microplate reader 
(Molecular Device, Devon, UK) 
Detection of IL-6 by enzyme-linked immunosorbent assay  
Supernatant protein concentrations of IL-6 were quantified by commercially available ELISA kit (BD 
Biosciences, CA, USA). After treatment with selected compounds for indicated times, the supernatants 
were collected. 96-well plate was coated with coating buffer containing primary antibody for mouse IL-
6 overnight at 4 °C. After washing with PBS-T (PBS containing 0.05% Tween-20), the wells were 
blocked with assay diluents. The plates were incubated for 1 h at room temperature. After 1 h, plates 
were washed and 100 l of samples or standards were added to the wells. After 2 h, plates were washed 
and 100 μL IL-6 detection antibody diluted 1:250 in assay diluent was added per well. Plates were 
incubated for a further 1 h before being washed. The enzyme streptavidin alkaline phosphatase was 
diluted 1:250 in assay diluent and 100 µL was added per well. Plates were then incubated for 30 min. 
After washing, substrate solution was added and incubated for 30 min in the dark. The reaction was 
stopped with 50 µL of 1 M H3PO4 (stop solution), and the absorbance of the wells was read at 450 nm 
with a correction of 570 nm using UV max kinetic microplate reader (Molecular Device, Devon, UK). 
IL-6 concentrations were calculated from the linear equation derived from the standard curve of known 
concentrations of purified mouse IL-6. 
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 signaling was measured with the calcium-sensitive dye Furo-4.  Cells were stained 
with 1 μg/ml Hoechst 33342 in medium for 30 min.  Then cells were washed with Hanks' balanced salt 
solution (HBSS) containing 20 mM HEPES and equilibrated with loading solution containing with 5 
M Furo-4, 2.5 mM probencid and 20 mM HEPES in HBSS for 30 min at 37 C and followed by 30 
min at room temperature.  After loading, cells were washed twice with HBSS in order to remove excess 
fluorescent dye.  Cells were then treated for different durations with various compounds in HBSS in a 
humidified incubator which provided an atmosphere of 5 % CO2 and 95 % air at a constant temperature 
of 37 °C.  The fluorescence intensity of fluo-4 was measured by using ArrayScan
®
 high-content 
screening system (Cellomics Inc, Pittsburgh, PA).  Measurements of fluorescent intensity with 
appropriate filter were captured with appropriate filter on 10 fields with each field containing 
approximately 500 cells.  Relative changes in calcium concentration using fluo-4 were analyzed as a 
function of time, were expressed as F/F (in %), with F being the baseline fluorescence and F the 
variation of fluorescence. 
Statistical analysis 
The data are expressed as the mean ± SD and were analyzed using one-way ANOVA (V5.00; GraphPad 
Prism Software Inc., San Diego, CA). When ANOVA showed significant differences between groups, 
Tukey’s post hoc test was used to determine the specific pairs of groups showing statistically significant 
differences. A p value of less than 0.05 was considered statistically significant. 
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Results 
Blockage of mGluR5 induced oxidative stress and inflammatory responses in BV-2 cells 
There is a close resemblance between BV2 microglial cells and primary microglia in terms of their 
inflammatory signaling pathways. Therefore, BV-2 microglial cells can be used as an appropriate model 
for the activation of microglia in vitro [67]. Upon activation, BV2 microglial cells are known to increase 
their production of neuroinflammatory molecules including iNOS, cytokines, and ROS. For the present 
study, we used, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) which is a specific antagonist for 
mGluR5 to mimic the situation of mGluR5 blockage. The intracellular redox status was evaluated with 
DHE, MitoTracker
®
Red CMXRos, and MitoSOX Red which are markers of ROS, mitochondrial mass, 
and ROS in mitochondria, respectively (Fig. 1A-Fig. 1C). In addition, the expression of iNOS mRNA 
was also investigated (Fig. 1D). The inflammatory responses of BV-2 cells were measured by both 
mRNA and protein levels of IL-6 (Fig. 1D and Fig. 1E). After a 24-h incubation time, the mGluR5 
antagonist, MPEP (100 M) induced a significant increase in oxidative stress parameters with 
132.24.56, 133.65.77, and 313.714.59% of intracellular ROS, mitochondrial mass, and 
intramitochondrial ROS, compared with control group, respectively. The level of iNOS mRNA was 
increased 3.040.23 fold compared with control. MPEP also enhanced the inflammatory responses of 
BV-2 cells by increasing IL-6 mRNA and protein expression by 6.230.85 and 29.203.25 fold 
respectively compared with control. In parallel, the biological effects of mGluR5 agonist CHPG (100 
M) on BV-2 cells were investigated. As expected, no significant changes were observed after 24 h of 
CHPG exposure. Moreover, the actions of mGluR5 were completely blocked when cells were pretreated 





Blockage of mGluR5 induced cellular energy depletion and disturbed AMPK phosphorylation 
Because mitochondrial dysfunction can result in alterations in oxidative stress and inflammatory 
responses, it may also affect ATP synthesis. We measured the intracellular ATP content in BV-2 cells 
following MPEP (100 M) exposure as shown in Fig. 2A. Total ATP content was significantly 
decreased 16.461.04% following incubation of cells with MPEP for 1 h compared to control. 
Interestingly, ATP production also decreased in time-dependent manner. This result demonstrates that a 
single dose of MPEP significantly affects ATP levels in BV-2 cells. 
The role of AMPK was examined because AMPK activation has influence on ATP production and the 
sensitivity of cells to such toxicants. DBT altered energy balance in BV-2 cells and consequently, the 
effects of AMPK inhibitor Compound C as well as AMPK activator (AICAR) on MPEP diminished 
ATP production were examined. Fig. 2B shows that treatment of cells with 1 μM Compound C alone 
resulted in a decreased in cellular ATP levels 71.514.68% compared to control. As expected, 
pretreating the cells with Compound C potentiated the toxicity of MPEP to reduced ATP levels to 
14.831.34%. On contrary, 1 mM AICAR alone slightly increased ATP production 133.07.28% 
compared to control. Pretreating the cells with AICAR completely reversed ATP depletion induced by 
MPEP exposure. These results suggest that AMPK may be involved in MPEP-induced ATP depletion. 
To examine whether MPEP and AICAR stimulated AMPK activation in BV-2 cells, the 
phosphorylation of AMPKα subunit was measured after the indicated chemicals treatment for 0.5, 1, 
and 2 h. Fig. 2C shows that the level of pAMPK increased in the presence of AICAR (1mM) or MPEP 
(100 M) for 1 h. However, no further increase in pAMPK levels was observed when the cells were 
treated with either AICAR or MPEP for 2h. These results suggest that AMPK is maximally activated in 
BV-2 cells after 1 h stimulation. 
To investigate if DBT-stimulated phosphorylation of AMPK can be further modulated by an inhibitor or 
an activator of AMPK, cells were pre-treated with either compound C (1 M) or AICAR (1mM) for 1 h, 
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and then co-exposed to MPEP (100 M) for 1h. The phosphorylation state of AMPK-induced by MPEP 
was reversed by compound C but enhanced by AICAR (Fig. 2D).  
 
mGluR5 increased intracellular calcium released from the endoplasmic reticulum 
Disturbances in [Ca
2+
]i regulate a wide variety of targets such as kinases, phosphatases, and 
transcriptional factors. The effects of MPEP on [Ca
2+
]i  were determined using a fluorescent indicator 
Fura-4. Cells were exposed to MPEP and kinetic [Ca
2+
]i changes were analysed every minute. In Ca
2+
-
free medium, MPEP (100 M) significantly increased [Ca2+]i in BV-2 cells (Fig. 3A). Next, we 
explored the specific intracellular Ca
2+
 store involved in MPEP-induced cytoplasmic [Ca
2+
]i rise. It has 
been shown that the endoplasmic reticulum (ER) is the major Ca
2+
 store in microglia cells. Fig. 3A 
shows that in Ca
2+
-free medium, the addition of MPEP (100 M) induced a substantial reduction of the 
amplitude of the [Ca
2+
]i response to thapsigargin, an ER Ca
2+
 pump inhibitor. Fig. 3B shows that 
thapsigargin induced a [Ca
2+
]i rise, and subsequently added MPEP (100 M) blocked the [Ca
2+
]i rise. 
To determine the specific receptors involved in the Ca
2+
 efflux from the ER following exposure to 
MPEP, we used two different inhibitors before MPEP treatment. We used dantrolene to inhibit 
ryanodine receptors (RyRs) in the ER [68] and xestospongin C as inhibitor of inositol triphosphate 
receptors (IP3Rs) in the ER. Inhibition of IP3R Ca
2+
-channels by xestospongin C in the ER partially 
prevented the increase in [Ca
2+
]i provoked by MPEP (Fig. 3D). However, pretreatment cells with 
dantrolene abolished an elevation of [Ca
2+
]i after MPEP exposure (Fig. 3C). 
 
Blockage of mGluR5 results in increasing of ER stress  
Disturbances in Ca
2+
 homeostasis can trigger ER stress and MPEP induced [Ca
2+
]i elevation. 
Consequently, we tested whether blockage of mGluR5 with MPEP induces ER stress. The expression of 
GRP78 protein was examined after cells were treated with MPEP for 0.5, 1, and 2 h by Western 
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blotting. MPEP treatment induced a time-dependent increase in GRP78 protein expression in BV-2 cells 
(Fig. 4A). Consistent with our hypothesis, the protein levels of GRP78 were elevated 1 h after MPEP 
exposure, with the maximal expression at 2 h. 
Furthermore, we also assessed the mRNA expression level of CHOP, GRP78, and GRP94 after MPEP 
exposure for 24 h. As shown in Fig. 4B, real-time PCR analysis showed that the expression of CHOP, 
as well as GRP78, and GRP94 mRNA increased significantly 3.540.25, 3.000.064, and 3.830.30 
fold respectively in response to MPEP treatment compared with control. To confirm the action of MPEP 
on ER stress, cells were pretreated for 1 h with 4-phenyl butyric acid (4-PBA), a chemical chaperone, 
and incubated with MPEP for 24 h. 4-PBA significantly reversed MPEP-induced mRNA expression of 
the major ER chaperone (Fig. 4B).  
DBT triggered the accumulation of cytosolic Ca
2+
 by enhancing Ca
2+
 release from ER (Fig. 3A and 3B) 
that in turn could trigger an ER stress response. This meant that blocking Ca
2+
 release by the calcium 
chelator BAPTA-AM could potentially inhibit ER stress-induced by MPEP. We therefore analyzed the 
effects of BAPTA-AM on MPEP-induced CHOP, GRP78, and GRP94 mRNA expression. Pretreatment 
of cells with BAPTA-AM (1 M) followed by MPEP treatment, blocked induction in expression of 
these three ER stress markers. This confirms that ER Ca
2+
 release is a critical element of the ER stress 
response. 
The results suggest that MPEP acts, at least in part, on AMPK pathways to regulate mitochondrial 
biogenesis and function in BV-2 cells (Fig. 2B-2D).  
To evaluate whether effect of MPEP on ER stress was mediated through AMPK, we examined the 
effect of AICAR and compound C on the protein level of GRP78 in BV-2 cells. We pretreated cells 
with either AICAR (1 mM) or compound C (1 M) for 1 h., followed by MPEP (100 M) for 2 h. 
AICAR or compound C treatment alone did not significantly interfere on GRP78 protein level (data not 
shown). As shown in Fig. 4C, compound C increased the potency of MPEP to enhance GRP78 level. In 
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contrast, activation of AMPK activity with AICAR reduced MPEP-induced GRP78 protein expression 
(Fig. 4B). To determine whether the alteration in of CHOP, GRP78, and GRP94 mRNA levels observed 
with MPEP treatment was the result of AMPK, we pretreated cells with either AICAR (1 mM) or 
compound C (1 M) for 1 h. then followed by co-incubation with MPEP (100 M) for 24 h and 
measured the levels of CHOP, GRP78, and GRP94 mRNA. As shown in Fig. 4D, AICAR partially 
abolished the increase in CHOP, GRP78, and GRP94 mRNA levels seen with MPEP treatment, again 
indicating that AMPK-regulated to energy balance may play a role in regulation of CHOP, GRP78, and 
GRP94 mRNA transcription. These findings strongly suggest that AMPK may mediate the action of 
MPEP on ER stress in BV-2 cells. 
 
Phospholipase C is the target of mGluR5 modulation  
It is widely accepted that activation of PLC produces IP3, which opens IP3Rs to induce Ca
2+
 release 
from the ER in a variety of cells. As such, we speculated that PLC may play a role in MPEP-induced 
Ca
2+
 elevation. As compared with the vehicle, as shown in Fig. 5A, MPEP increased the intracellular 
calcium concentration in a concentration dependent manner. We also pretreated cells with an inhibitor 
of PLC, U73122, at an effective concentration (5 μM) and the response of MPEP (100 µM) was 
significantly inhibited MPEP induced increases in CHOP, GRP78, and GRP 96 mRNA expression were 
also reduced by pretreatment with U73122 (Fig. 5B). These results demonstrated that PLC may play a 
role in MPEP-induced Ca
2+
 elevation and ER stress. To address this issue, we investigate whether 
MPEP could activate PLC in BV-2 cells. The results are shown in Fig. 5C, in which total PLC activity 
was significantly increased in cells following MPEP exposure for 2 h compared with control. The 
MPEP induced increase in the activity of total PLC was completely blocked by pretreatment with 
U73122 for 1 h. In addition, U73122 also significantly decreased on the basal activity of PLC in BV-2 
cells (Fig. 4C). 
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To evaluate if PLC was involved in the Ca
2+
-dependent processes we used U73122 as an inhibitor of 
PLC and BAPTA-AM and studied their effect on the GRP78 protein levels-mediated by MPEP (Fig. 
5D). U73122 blocked the MPEP-induced response completely, indicating that PLC is involved in 
GRP78 expression. Pretreating the cells with BAPTA-AM also abolished the action of MPEP t 
confirming that calcium is directly involved in MPEP-induced ER stress. 
 
PTX-sensitive G proteins/PLC/ Ca
2+
 pathways mediated by mGluR5 
Several studies have demonstrated that G protein-coupled receptors may exert their effects through 
activation of PLC, which hydrolyzes phospholipids in cell membrane to IP3 and DAG. To investigate 
the [Ca
2+
]i responses to MPEP, we pretreated cells with a specific inhibitor of Gi/o-type G proteins, 
pertussis toxin (PTX; 100 ng/ml) for 6 h. As shown in Fig. 6A, pretreatment of cells with PTX 
completely suppressed [Ca
2+
]i release induced by MPEP treatment suggesting the involvement of Gi/o 
proteins in [Ca
2+
]i responses to MPEP. 
We showed that MPEP activated PLC activity and PTX blocked [Ca
2+
]i induced by MPEP. Therefore, 
we investigated whether PTX inhibit MPEP-activated PLC activity. As shown in Fig. 6B, the actions of 
the MPEP were markedly inhibited by PTX pretreatment. This result suggests that MPEP may utilize 
PTX-sensitive G-protein in the PLC activation. 
To confirm the downstream effects of MPEP after PLC activation and increase in [Ca
2+
]i, we 
investigated whether PTX suppresses GRP78 expression after MPEP exposure. As shown in Fig. 6C, 
pretreatment cells with PTX completely inhibited the action of MPEP on GRP78 synthesis. 
 




The role of mGluR5 and intracellular signaling on the regulation of oxidative stress and inflammatory 
responses were confirmed by pretreating the cells with AICAR, compound C, BAPTA-AM, U73122, or 
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PTX (AMPK activator, AMPK inhibitor, Ca
2+
 chelator, PLC inhibitor, and Gi/o-type G protein inhibitor, 
respectively) followed by MPEP exposure. Consequently, the levels of intracellular ROS, mitochondrial 
mass, mitochondrial ROS, iNOS mRNA, IL-6 mRNA, and IL-6 protein were measured. Pretreatment of 
cells with coumpound C potentiated the actions of MPEP on oxidative stress and cytokine expression 
(Fig. 7A-7F). On contrary, AICAR, BAPTA-AM, U73122, and PTX could prevent the action of MPEP 
on total ROS production and ROS-generated in the mitochondria (Fig. 7A and 7C) as well as preventing 
the mitochondrial toxicity of MPEP as indicated by mitochondrial mass (Fig. 7B). Moreover, these 
chemicals markedly attenuated MPEP-induced iNOS IL-6 mRNA levels as well as IL-6 expression 
(Fig. 7C-7D). These data suggested that blockage of mGluR5 by MPEP may modulate PTX-sensitive G 
proteins, PLC, AMPK, and [Ca
2+
]i and contribute to oxidative stress and inflammatiory responses in 
BV-2 cells. 
Discussion 
Several reports have shown that the metabotropic glutamate receptor 5 (mGluR5) mediates 
neuroprotective effects in microglia cells by the modulation of oxidative stress and inflammatory 
cytokine release both in vitro and in vivo. It was demonstrated that the mGluR5 agonist, (R,S)-2-chloro-
5-hydroxyphenylglycine (CHPG) reduced NF-κB activity and nitrite production in lipopolysaccharide-
stimulated microglia and improved functional recovery after traumatic brain injury [10, 15, 16]. 
Activation of mGlu5 receptors abolished the toxic effect produced by 1-methyl-4-phenylpyridinium in 
SK-N-SH cells [69]. Delayed CHPG administration reduced chronic neuroinflammation and associated 
neurodegeneration after experimental traumatic brain injury in mice [7]. Stimulation of mGluR5 
reduced ROS production, NO production, proliferation and TNF-α production in microlgia cells after 
LPS exposure [8]. In addition, the expression and the distribution of mGluR5 was changed after brain 
damage [15, 70]. mGluR5 is down-regulated in activated microglia by proinflammatiory cytokine 
stimulation[71].  
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However, the consequence of direct antagonism of the mGluR5 on the cellular functions of microlgia 
has yet to be studied. Therefore, in the present study, we used 2-methyl-6-phenylethynyl-pyridine 
(MPEP), a non-competitive mGluR5 antagonist, to block mGluR5 in BV-2 cells and we measured the 
oxidative stress and inflammatory responses. MPEP increased the total ROS production as well as 
mitochondrial dysfunction representing with mitochondrial swelling and ROS. MPEP enhanced the 
inflammatory response by increasing IL-6 expression and release of microglia. CHPG completely 
reversed the actions of MPEP. This indicates that oxidative stress and cytokine up-regulation induced 
by MPEP through mGluR5 inactivation. These results are consistent with the previous studies which 
found that activation of mGluR5 in microglia cells protect neuronal cells and prevent brain damage [7-
10, 69]. However, MPEP has been shown the neuroprotection in several investigations. In particular, 
prolonged treatment with MPEP prevented excitotoxic death of cultured spinal cord motor neurons [72]. 
6-hydroxydopamine induced nigrostriatal lesions was abrogated following MPEP administration [73]. 
Mitochondrial dysfunction leading to ATP depletion has been suggested to be implicated in an increase 
in oxidative stress and inflammation [74-77]. Consequently, the downstream effect of mGluR5 blockage 
on cellular ATP content was investigated. Cellular ATP content was decreased after mGluR5 blockage 
by MPEP within 1 h. The involvement of AMPK was tested. Pretreatment of cells with compound C, an 
AMPK inhibitor, enhanced the action of MPEP but pretreatment cells with AICAR prevented ATP 
depletion. This was considered to be related to the production of inflammatory mediators [78, 79]. 
AICAR inhibited the proinflammatory response in glial cells [78]. However, AMPK is activated by 
phosphorylation after depletion of ATP levels [80]. Activation of AMPK has been reported to enhance 
apoptosis, ROS production, and cytokine release [81-83]. AMPK phosphorylation by MPEP increased 
after 1 h while significant ATP depletion was observed. These results indicate that a blockage of 
mGluR5 may influence AMPK activation through the inhibition of ATP production. Our observations 
show the first evidence of an association between inhibition of mGluR5 and the activation of AMPK 
signaling that involved energy balance in microglia cells. 
112 
Calcium disturbances have implications for the health and function of many types of cells for instance 





]i) represent one of the major pathways for signal 
transduction in microglia. LPS leads a chronic elevation of basal [Ca
2+
]i and BAPTA strongly prevented 
the LPS-induced release of NO and the cytokines TNFα, IL-6, and IL-12 [88]. Some studies have 
indicated that intracellular calcium may act directly on the mitochondrial membrane, leading to 
enhanced ROS production [89, 90]. It is also indicated that intracellular calcium elevation could 
enhance ROS production in various culture cells, such as astrocytes [91, 92], neurons [93], and 
microglia cells [86, 94]. Overload of calcium also decreases mitochondrial function by triggering the 
opening of the mitochondria permeability transition pore and results in mitochondrial swelling, increase 
in the generation of ROS, mitochondrial membrane depolarization and decrease in the production of 
ATP [95-97]. Accordingly, we hypothesized that MPEP might promote oxidative stress as well as pro-
inflammatory cytokine up-regulation through increasing intracellular calcium in microglia cells. As 
shown in Fig. 3A, exposure of BV-2 cells to MPEP caused a burst of fluorescence intensity that reaches 
a peak at 15 min and returned to baseline within 40 min. Previous studies showed that microglial Ca
2+
 
signals occur predominantly under pathological conditions [42]. For example, an exposure to Aβ 
increased ([Ca
2+
]i in cultured microglia. Basal [Ca
2+
]i levels in microglia isolated from the brain of AD 
patients is higher than that of microglia from non-demented individuals [98, 99]. Increase of 
intracellular ([Ca
2+
]i can be elicited through two main mechanisms; firstly, mobilization of Ca
2+
 from 
intracellular stores and secondly, entry from the extracellular space through the opening of plasma 
membrane Ca
2+





-free medium condition. This strategy showed that [Ca
2+
]i induced by MPEP originated from 
intracellular organelles and not extracellular influx. In addition, the endoplasmic reticulum (ER) is a 
intracellular storage compartment for calcium in microglia cells [44]. In our study, pre-exposure of BV-
2 cells to thapsigargin completely blocked MPEP-induced [Ca
2+
]i elevation and conversely, MPEP 
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pretreatment also reduced thapsigargin-induced [Ca
2+
]i level. Therefore, these results confirm that 
MPEP increased [Ca
2+
]i because of ER perturbation. We then identified the specific receptors 
modulating MPEP induced calcium release from the ER, inositol 1,4,5-trisphosphate (IP3R) not the 
ryanodine (RyRs) receptors [100]. We found that xestospongin C, IP3R receptor antagonist, 
significantly blocked MPEP-induced [Ca
2+
]i rise. However, RyRs receptor antagonist, dantolene only 
partially diminished [Ca
2+
]i induced by MPEP indicating that mGluR5 may modulate through the IP3R 
receptor. Moreover, these results are agreement with previous observation showing that xestospongin C 
prevented the induction of TNF-α and IL-6 in microglia cells [101].  
The depletion of luminal ER calcium stores is believed to trigger ER stress which activates the unfolded 
protein response (UPR) pathway to induce the expression of ER chaperone proteins, such as CHOP, 
GRP78, and GRP96 [49]. In our study found that MPEP treatment enhanced the expression of ER stress 
proteins (CHOP, GRP78, and GRP96) in BV-2 cells and was strongly attenuated by BAPTA-AM, 
suggesting that mGluR5 modulate ER stress through [Ca
2+
]i homeostasis. Not only intracellular calcium 
dysregulation but AMPK has been documented to be involved in ER stress in several cells [52, 53, 56, 
102]. MPEP was able to disturb AMPK function and led to a decrease in ATP production and we found 
that compound C promoted ER stress induced by MPEP. Conversely, AICAR reversed the action. In 
addition, pretreatment of either compound C or AICAR had no effect on [Ca
2+
]i (data not shown) 
suggesting that the action of AMPK on MPEP-mediated ER stress is independent of [Ca
2+
]i but related 
to energy balance. AMPK activation has already been shown to be involved in cell energy metabolism 
through elevation in fatty acid oxidation and levels ATP increased following AICAR stimulation [103]. 
Accordingly, incubation with AICAR has been reported to protect endothelial cells from a loss of 
intracellular ATP induced by hyperglycemia [104]. The protective potential of AICAR on ER stress has 
been documented [52, 105-108]. However, an activation of AMPK was reported to potentiated ER 
stress [7, 36, 56]. 
114 
PLC activation induces IP3 production, resulting in the release of Ca
2+
 from ER through the IP3 
receptor. We found that U73122, a PLC inhibitor, abrogated MPEP-induced Ca
2+
 increases and ER 
stress. BAPTA-AM prevented MPEP-induced ER stress. Taken together, these results demonstrate that 
MPEP induces ER stress via the PLC-IP3 pathway. MPEP increased PLC activity supporting our 
hypothesis. However, there is evidence that the mGluR5 agonist, CHPG reduced inflammation induced 
by LPS in microglia this was associated with phospholipase C activation and an increase in intracellular 
calcium [8]. It is possible that mGluR5 might cross regulate a toll-like receptor and resulting in a muted 
inflammatory response.  
To examine the possible involvement of G proteins, cells were pretreated with PTX which completely 
inhibits the effect of MPEP on PLC activation, [Ca
2+
]i rise, ER stress, oxidative stress responses and 
pro-inflammatory cytokine release. Classically, the activation of PLC resulting in the synthesis of IP3 
and the release of Ca
2+
 from ER, was linked to Gq-coupled receptors [57]. In the present study, the 
MPEP-induced increase in [Ca
2+
]i was attenuated by PTX (an inhibitor of Gi protein), U73122 (a PLC 
inhibitor), and xestospongin C (an IP3 receptor antagonist). Crosstalk among mGluR5 receptors to 
modulate PLC through Gi-protein subunits is possible, because several studies in a variety of cells and 
tissues demonstrated that the mobilization of [Ca
2+
]i is stimulated by Gi-coupled receptors [57, 61, 109]. 
For instance, PTX treatment of natural killer cells reduced [Ca
2+
]i release and chemotaxic induction 
[61]. Chronic activation of Gi-proteins interferred with basal L-type Ca²⁺ channel activity in heart 
failure [110]. PTX totally blocked the Ca²⁺ responses induced by endomorphin-1 (an endogenous μ-
opioid receptor agonist) in astrocytes [111].  
Our study is the first that describes the direct effect of mGluR5 antagonism on oxidative stress, 
inflammation and ER stress mediated by Ca
2+
 homeostasis through PTX-sensitive G 
protein/PLC/IP3/Ca
2+
 pathway. In addition, the Ca
2+
 independent AMPK also is involved in mGluR 




In summary, the present study demonstrates that antagonism of mGluR5 in BV-2 cells results in 
increased oxidative stress including ROS production and mitochondrial dysfunction as well as 
enhancing inflammatory responses exhibited by an up-regulation of pro-inflammatory cytokines. 
mGluR5 may modulate the action via a Ca
2+
-dependent pathway involving PTX-sensitive G protein. 
Accumulation of [Ca
2+
]i originating from ER is suggested to be via the PI3 receptor which is regulated 
by PLC and the PTX-sensitive G protein. Antagonism of mGluR5 decreased ATP production which 
was reversed by APK activation. Therefore, mGluR5 might also regulate energy balance through 
AMPK activation. Our study suggests that according mGluR5 antagonist through Ca
2+
-dependent 
pathways and the AMPK pathway may act separately or in concert to regulate the redox status, 





]i, free intracellular Ca
2+
; AMPK, AMP-dependent protein kinase; ATF6, activating transcription 
factor 6; CHOP, transcriptional factor C/EBP homologous protein; CHPG, (RS)-2-chloro-5-
hydroxyphenylglycine; CNS, central nervous system; DEPC, diethylpyrocarbonate; DHE, 
dihydroethidium; DMEM, Dulbecco's modified Eagle's medium; ELISA, enzyme-linked 
immunosorbent assay; ER, endoplasmic recticulum; ERK1/2, extracellular signal-regulated protein 
kinase1/2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GPCR, G protein-coupled receptor; 
GRP78, glucose-regulated protein 78; GRP94, glucose-regulated protein 94; HBSS, Hank’s balanced 
salt solution; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HRP, Horseradish 
peroxidase; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; IP3, inositol trisphosphate; IP3R, 
1,4,5-trisphosphate receptor; IRE1, inositol-requiring enzyme-1; MAPKs, mitogen-activated protein 
kinases; mGluR5, metabotropic glutamate receptor 5; MPEP, 2-methyl-6-(phenylethynyl)-pyridine; 
NEAA, non-essential amino acids; NF-κB, Nuclear factor kappaB; NO, nitric oxide; NOX-2, NADPH 
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oxidase type 2; PBA, sodium phenylbutyrate; PDVF, polyvinylidene difluoride; PERK, PKR-like ER 
kinase; PKC, protein kinase C; PLC, phospholipase C; PTX, pertusis toxin; RIPA, radio 
immunoprecipitation assay; ROS, reactive oxygen species; RyR, ryanodine receptor; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TBS, Tris-buffered saline; TBS-T, Tris-
buffered saline with Tween; UPR, unfolded protein response 
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Figures and Figure Legend 
 
 
Figure 1. Blockage of mGluR5 induced mitochondria dysfunction in BV-2 cells. Cells were treated 
with either CHPG or MPEP for 24 h. A, Intracellular ROS levels were determined using DHE. B, 
Mitochondrial content was determined using MitoTracker
®
Red CMXRos. C, Mitochondrial ROS levels 
were determined using MitoSOX Red. D, iNOS mRNA expression and bar graphs representing 
iNOS/GAPDH ratios. E, IL-6 mRNA expression and bar graphs representing IL-6/GAPDH ratios. F, 
IL-6 protein. Results were expressed as the mean ± SD of at least 3 experiments and significant was 
determined by one-way ANOVA followed by Turkey’s tests, *p < 0.05, **p < 0.01; ***p < 0.005 
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Figure 2. Blockage of mGluR5 induced cellular energy depletion mediated by AMPK. A, MPEP 
decreased ATP levels in a time dependent manner. Cells were treated with MPEP (100 μM) for for 1, 2, 
3, and 4 hr. B, AMPK inhibitor potentiated the action of MPEP on ATP production. Cells were treated 
for 2 hr. with 100 μM MPEP alone or in combination, with or without 1 μM compound C or 1 mM 
AICAR. The total cellular levels of ATP were analyzed as described in Materials and methods. Results 
were expressed as the mean ± SD of at least 3 experiments and significant was determined by one-way 
ANOVA followed by Turkey’s tests, *p < 0.05, **p < 0.01; ***p < 0.005. C, MPEP changed AMPKα 
phosphorylation in BV-2 cells. Immunoblot analyses were performed on lysates of BV-2 cells that had 
been treated with MPEP, and AICAR (positive control) for the indicated time period. (D) Immunoblot 
analyse as performed on lysates of BV-2 cells that had been pre-incubated with either AICAR (1 mM) 
or compound C (1 M) then cells were exposed with MPEP for 2 h. 
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Figure 3. MPEP induced Ca
2+
 release from ER. Experiments were performed in Ca
2+
-free medium. 
(A) Effect of thapsigargin (1 μM) on the kinetics of cytosolic Ca2+ increases induced by MPEP (100 
μM) in Fura-4 loaded BV-2 cells. The    symbols indicate the trace of relative changes in of [Ca2+]i after 
exposure to MPEP (100 μM) for 60 min and followed by thapsigargin (1 μM) alone. The    symbols 
indicate the trace of relative changes in of [Ca
2+
]i after exposure to thapsigargin (1 μM) at the time point 
of 60 min. (B) Effect of MPEP (100 μM) on the kinetics of cytosolic Ca2+ increases induced by 
thapsigargin (1 μM) in Fura-4 loaded BV-2 cells. The     symbols indicate the trace of relative changes 
in of [Ca
2+
]i after exposure to thapsigargin (1 μM) for 60 min and followed by MPEP (100 μM).              
The   symbols indicate the trace of relative changes in of [Ca
2+
]i after exposure to MPEP (100 μM) 
alone at the time point of 60 min. (C) Effect of dantolene (50 μM) on the kinetics of cytosolic Ca2+ 
increases induced by MPEP (100 μM) in Fura-4 loaded BV-2 cells. Cells were pre-treated with 50 M 
dantolene for 1 h. before loading with Fuo-4 and then cells were added with 100 M MPEP. (D) Effect 
of xestospongin C (5 μM) on the kinetics of cytosolic Ca2+ increases induced by MPEP (100 μM) in 
Fura-4 loaded BV-2 cells. Cells were pre-treated with 5 M xestospongin C for 1 h. before loading with 
Fuo-4 and then cells were added with 100 M MPEP. Relative changes in calcium concentration using 
fluo-4 were analyzed, and were expressed as F/F (in %), with F being the baseline fluorescence and 
F the variation of fluorescence. Data are expressed as mean ± SD. 
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 Figure 4. Blockage of mGluR5 results in increasing of ER stress. A, MPEP increased GRP78 protein 
levels. Immunoblot analyze as performed on lysates of BV-2 cells that had been treated with MPEP for 
the indicated time period. B, BAPTA-AM and PBA blocked MPEP-induced ER stress marker mRNA 
expression. Cells were pre-exposed with BAPTA-AMP (1 M) or PBA (1 mM) for 1 h. Expression of 
CHOP, GRP78, and GRP94 was measured by RT-PCR after exposure to 100 M MPEP for 24 hr. C, 
AMPK is involved in MPEP increased GRP78 protein levels.  Cells were pre-exposed with AICAR (1 
mM) or compound C (1 M) for 1 h. GRP78 protein levels was analyses by immunoblot after exposure 
to 100 M MPEP for 2 hr. D, Cells were pre-exposed with AICAR (1 mM) or compound C (1 M) for 
1 h. Expression of CHOP, GRP78, and GRP94 was measured by RT-PCR after exposure to 50 nM DBT 
for 24 hr. mRNA expression levels were normalized to GAPDH and plotted relative to the control 
value. Results were expressed as the mean ± SD of at least 3 experiments and significant was 
determined by one-way ANOVA followed by Turkey’s tests, *p < 0.05, **p < 0.01; ***p < 0.005 
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 Figure5. Blockage of mGluR5 activated phospholipase C pathway. A, MPEP induced intracellular 
calcium level mediated by Phospholipase C. Intracellular calcium was determined by detecting the 
fluorescence intensity with fluorochrome Fluo-4. BV-2 cells were pre-treated with 5 M U731221 for 1 
h. before loading with Fuo-4 and 100 M MPEP was added to the cells in the absence of extracellular 
calcium. Relative changes in calcium concentration using fluo-4 were analyzed at the maximum level 
(15 min.), were expressed as F/F (in %), with F being the baseline fluorescence and F the variation of 
fluorescence. Data are expressed as mean ± SD. B, Phospholipase C inhibitor (U731221) abolished 
MPEP and DBT-induced ER stress markers expression. C, mGluR5 increased phospholipase C. BV-2 
cells were pre-treated with CHPG or MPEP for 2hr.  Phosholipase activity presents as mU per g 




Figure 6. PTX-sensitive G proteins/PLC/Ca
2+
 pathways mediated by mGluR5. A, Pertussis toxin 
inhibited action of MPEP on calcium level. Intracellular calcium was determined by detecting the 
fluorescence intensity with fluorochrome Fluo-4. BV-2 cells were pre-treated with 100 ng/ml PTX for 6 
hr before loading with Fuo-4 and then 100 M MPEP was added to the cells in the absence of 
extracellular calcium. Relative changes in calcium concentration using fluo-4 were analyzed at the 
maximum level (15 min.), were expressed as F/F (in %), with F being the baseline fluorescence and 
F the variation of fluorescence. B, Pertussis toxin inhibited action of MPEP on phospholipase C 
activity. BV-2 cells were pre-treated with 100ng/ml PTX for 6 h exposed to 100 M MPEP for 2 hr. 
Phospholipase activity C presents as mU per g protein. Results were expressed as the mean ± SD of at 
least 3 experiments and significant was determined by one-way ANOVA followed by Turkey’s tests, *p 
< 0.05, **p < 0.01; ***p < 0.005. C, Pertussis toxin inhibited action of MPEP on GRP78 protein 
expression. Western blot analysis using antibodies against GRP78 protein expression in cells treated 
with indicated chemicals. Representative blots from 3 independent experiments. 
135 
 Figure 7. Blockage of mGluR5 induced mitochondria dysfunction in BV-2 cells mediated by PTX-
sensitive G proteins/PLC/AMPK/ Ca
2+
 pathways. Cells were pretreated with compound C (1 M) or 
BAPTA-AM (1 M) or U-73122 (1 M) for 1 hr or PTX (100 ng/ml) for 6 hr then exposed to MPEP 
(100 M) for 24 hr. A, Intracellular ROS levels were determined using DHE. B, Mitochondrial content 
was determined using MitoTracker
®
Red CMXRos. C, Mitochondrial ROS levels were determined using 
MitoSOX Red. D, iNOS mRNA expression and bar graphs representing iNOS/GAPDH ratios. E, IL-6 
mRNA expression and bar graphs representing IL-6/GAPDH ratios. F, IL-6 protein. Results were 
expressed as the mean ± SD of at least 3 experiments and significant was determined by one-way 





Real-time PCR primers 
Genes Primers Sequences 
GAPDH (mouse) forward  CTCGTGGAGTCTACTGGTGT 
reverse GTCATCATACTTGGCAGGTT 
IL-6 (mouse) forward  GGAGGCTTAATTACACATGTT 
reverse TGATTTCAAGATGAATTGGAT 
TNF- (mouse) forward  TTCTGTCTACTGAACTTCGG 
reverse GTATGAGATAGCAAATCGGC 
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Several reports suggest that the mechanism of trimethyltin (TMT) induced neurotoxicity involves the 
activation of microglia and endogenous glucocorticoid levels may play a role. The molecular 
mechanisms of TMT induced inflammation in microglia have not been investigated. Therefore the 
objectives of this research were to; (1) assess whether TMT induces proinflammatory mediator 
expression and if glucocorticoids can influence these changes. (2) investigate the possible mechanisms 
for such an induction. TMT induced the expression of interleukin-6 (IL-6) and inducible nitric oxide 
synthase (iNOS) in concentration dependent manner in BV-2 microglia cells. Pretreatment with a 
nuclear factor kappa B (NF-B) inhibitor blocked the action of TMT. TMT induced translocation of 
NF-B into nucleus. PD98059 and SB20190, inhibitors of ERK1/2 and p38 MAPK, respectively, 
inhibited the ability of TMT to induce IL-6 and iNOS expression. Interestingly, the proinflammatory 
action of TMT was substantially enhanced by corticosterone and 11-dehydrocorticosterone but 
suppressed by dexamethasone. Spironolactone, a MR antagonist not only blocked the action of TMT 
alone but also the potentiation effect of corticosterone on proinflammatory mediator expression. 
Similarly, the potentiation effect of corticosterone was inhibited by PD98059 and SB20190. An 
inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), BNW-16, also blocked TMT-
induced inflammation. 11β-HSD1 mRNA expression and activity were induced by TMT. 
Pharmacological manipulations indicated that NF-B, ERK1/2, and p38 activation mediated by MR and 
GR are involved in the observed 11β-HSD1 mRNA induction. These results suggest that TMT and 
corticosterone may act through the same signaling pathways to activate inflammation. Within the 
context of inflammation, increased expression of proinflammatory mediators by TMT and endogenous 
glucocorticoids could be critical part of mechanism by which TMT exerts its neurotoxicity. 




Trimethyltin chloride (TMT) is a classic neurotoxicant. TMT can accumulate in the body and pose a 
risk for workers chronically exposed to low doses. Animals exposed to TMT develop neurobehavioral 
changes (Tang et al., 2013). TMT-induced neurotoxicity by interfering with synaptic and 
neurodegeneration related networks, protein processing and degradation pathways (Little et al., 2012). 
One of the proposed mechanisms for TMT inducing neurotoxicity is the induction of the inflammatory 
response. Memory dysfunction induced by TMT in rat was observed, accompanied by an upregulation 
of reactive microglia marker and proinflammatory cytokine mRNA (Koda et al., 2009). TMT treatment 
induced the inflammatory response in adipocytes (Ravanan et al., 2011). In addition, TMT induced 
apoptosis in human neuroblastoma cells through activation of nuclear factor kappa B (NF-κB), c-Jun N-
terminal kinase (JNK), extracellular signal–regulated kinases (ERKs), p38 mitogen-activated protein 
kinase (p38 MAPK) (Qing et al., 2013).  
Increasing evidence indicates that the resident brain microglial immune cells contribute to 
neuroinflammation and result in the progression of neurodegenerative diseases through the release of 
pro-inflammatory mediators (Glass et al., 2010;Evans et al., 2013;Niranjan, 2013;Orre et al., 2013). 
Pro-inflammatory cytokines released from microglia such as interleukins-6 (IL-6), interleukins-1 (IL-
1β), and tumor necrosis factor (TNF-) play critical roles in microglia-mediated neurodegeneration 
(Smith et al., 2012;Ghosh et al., 2013;Qin et al., 2013). Nitric oxide (NO), produced by inducible nitric 
oxide synthase (iNOS) in microglia, is a well characterized pro-inflammatory factor that induce 
neuronal death (Brown and Neher, 2010;Li et al., 2012;Khasnavis et al., 2013). In addition, 
glucocorticoid-induced TNFR family related gene (GITR) is also suggested to play a role in the 
inflammatory response in microglia cells which contribute to inflammatory diseases (Cuzzocrea et al., 
2007;Santucci et al., 2007;Motta et al., 2009;You et al., 2009). 
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The activation of NF-κB mediates the expression of pro-inflammatory factors including interleukins, 
TNF-α and iNOS (Cheng et al., 2009;Lukiw, 2012;Wongchana and Palaga, 2012). In quiescent cells, 
NF-κB which exists primarily as a p50/p65 heterodimer remains inactive in the cytoplasm due to the 
formation of complexes with the inhibitory protein nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha (IκBα). Upon stimulation, IκBα is degraded, which then allows NF-
κB to translocate to the nucleus, bind to cognate DNA binding sites, and initiate the transcription of 
target proinflammatory genes (Barnes and Karin, 1997;Lukiw, 2012). MAPKs are serine and threonine 
protein kinases that function in multiple pathways and cell types. The MAPK family includes 
extracellular ERK1/2, JNK, and p38 (Waskiewicz and Cooper, 1995;Kolch, 2005), which have been 
implicated in the release of immune-related cytotoxic factors such as iNOS, COX-2, and 
proinflammatory cytokines (Choi et al., 2009;Lin et al., 2010;Wang et al., 2011b). 
Interestingly, several studies show that stress and glucocorticoids can enhance neuroinflammation. For 
example, stress-induced priming of subsequent CNS pro-inflammatory cytokine production has been 
documented to worsen mortality in a rat stroke model (Caso et al., 2006). Stress enhances spinal 
neuroinflammatory responses leading to cell death (Grau et al., 2004). While glucocorticoids have long 
been used for anti-inflammatory therapy, there is increasing evidence that glucocorticoids, major 
hormones released during periods of stress, potentiate proinflammatory cytokine production following a 
subsequent immune challenge (Yeager et al., 2009;Frank et al., 2010). For example, prior exposure to 
corticosterone potentiates lipopolysaccharide (LPS) induced spinal neuroinflammation by elevating of 
IL-1β and IL-6 levels (Loram et al., 2011). In addition, elevation of corticosterone levels was found to 
be proinflammatory to exacerbate LPS regulation of NF-κB, MAPKs, and proinflammatory gene 
expression in the frontal cortex (Munhoz et al., 2010). In tissue, the action of glucocorticoids is 
regulated by activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) (Tomlinson et al., 
2004;Cooper and Stewart, 2009). This enzyme converts inactive glucocorticoids such as cortisone and 
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dehydrocorticosterone to their active forms, cortisol and corticosterone, respectively. 11β-HSD1 is 
highly expressed in many areas of the brain, including the hippocampus, cerebellum, and neocortex 
(Moisan et al., 1990). The expression of 11β-HSD1 in microglia cells was observed and was proposed 
to modulate neuroinflammation and brain functions (Gottfried-Blackmore et al., 2010). Moreover, 11β-
HSD1 expression is modulated by NF-κB and MAPKs which involves in cytokine expression (Ishii-
Yonemoto et al., 2010;Ahasan et al., 2012). 
Corticosteroids such as corticosterone and cortisol mediate their effects by binding to either 
mineralocorticoid receptors (MR) or glucocorticoid receptors (GR) with different affinities. MR 
expressed on microglia may play a role in the modulation of microglia activity (Frieler et al., 2011). 
Evidence suggests that spironolactone, an MR antagonist, inhibits the production of several pro-
inflammatory cytokines, including TNF-α and IL-1β and shows positive effects in patients with 
immunoinflammatory diseases (Hansen et al., 2004;Miura et al., 2006;Syngle et al., 2013). It has been 
reported that spironolactone could block MR regulated microglial activation mediated by corticosterone 
and aldosterone on microglial activation (Tanaka et al., 1997). However, corticosterone inhibits the 
proliferation of microglia cells through GR, not MR (Nakatani et al., 2012). In mice, microglial GR 
protected dopaminergic neurons after acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
intoxication. Microglial GR gene inactivation exacerbated both microglial and astroglial reactivity after 
acute MPTP treatment (Ros-Bernal et al., 2011). Both MR and GR differentially regulate the function of 
MAPKs and NF-κB (Kiyomoto et al., 2008;Nguyen Dinh Cat et al., 2011;Chantong et al., 
2012;Queisser et al., 2013). To date, however, there are no findings on the roles of MR and GR in 
TMT-induced inflammation in the murine microglia cells. 
Reports reveal the involvement of endogenous corticosterone in the pathological phenomena related to 
TMT toxicity. Specifically, plasma coricosterone concentrations transiently increased in the TMT-
treated rats (Shirakawa et al., 2007) together with neuropathological changes, behavioral changes 
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(Tsutsumi et al., 2002), and elevated hippocampal necrosis (Imai et al., 1998). In mice, time-and 
concentration-dependent changes in plasma corticosterone were also observed following TMT injection 
(Ogita et al., 2012). Both endogenous and exogenous glucocorticoids prevented neuronal degeneration 
induced by TMT in the mouse brain (Shuto et al., 2009a). In addition, it has been proposed that the 
extent TMT cytotoxicity is dependent on the balance between GR and MR activity. Spironolactone 
protects neurons in the dentate granule cell layer from TMT cytotoxicity. The GR antagonist 
mifepristone potentiated the TMT cytotoxicity in neurons (Ogita et al., 2012). However, it is still 
unclear whether corticosterone acts as a protective or as a deleterious factor in TMT induced 
inflammation. 
We are interested in the proinflammatory mechanisms mediated by TMT, particularly the NF-κB and 
MAPKs pathways and the expression of iNOS and/or IL-6 in microglia cells. The role and the 
regulation of glucocorticoids on the action of TMT were also investigated. Microglial BV-2 cells were 
used in the present study. This cell line exhibits many of the morphological, phenotypic, and functional 
properties of freshly isolated microglial cells (Blasi et al., 1990;Juknat et al., 2012) and has long been 
used as a research model of microglial cells (Lee et al., 2010;Juknat et al., 2012). These studies 
provided mechanistic evidence of TMT activity at low concentration in inflammatory-responsive glial 
cells. MR mediates the inflammatory response-induced by TMT through NF-κB, ERK1/2, p38. The 
potentiation of TMT-stimulated inflammation by corticosterone depends on the local glucocorticoid 
balance which is regulated by 11β-HSD1. TMT was shown to directly induce 11β-HSD1 mRNA 





MATERIAL AND METHODS 
Chemicals 
Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 medium, penicillin, streptomycin, 0.05% 
(w/v) trypsin/EDTA, non-essential amino acids (NEAA), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Hank’s balanced salt solution (HBSS), Hoechst 33342, were 
obtained from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum was from Atlanta Biologicals 
(Lawenceville, GA, US). ELISA kit for IL-6 was purchased from BD Biosciences, (BD Biosciences, 
CA, US). Cellomics HCS reagent kits evaluation size NF B activation (K010011) was obtained by 
Cellomics, Inc (Cellomics, Inc, Pittsburgh, PA, USA). Cay-10512 was from Cayman Chemicals 
(Hamburg, Germany). [1,2-
3
H]-cortisone from American Radiolabeled Chemicals (St. Louis, MO, 
USA). Extracellular signal-regulated kinase (ERK)1/2, p38 and JNK inhibitors (PD98059, SB202190 
and SP600125, respectively), trimethyltin chloride (TMT), sodium dodecyl sulphate, 
polyacrylamide/bis-acrylamide, Tween-20, -mercaptoethanol, and dimethylsulfoxide were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Specific antibodies against AMPK, ERK1/2, p38 MAPK, 
JNK, NF-B (p65) and their phosphorylated forms were obtained from Cell Signaling Technology 
(Danvers, MA, USA). Specific antibodies for β-actin and goat anti-rabbit IgG- horseradish peroxidase 
were obtained from Santa Cruz Biotechnology (Santa, CA, USA). 
Cell culture 
The mouse BV-2 microglial cell line (obtained from Professor Wolfgang Sattler, University of Graz, 
Graz, Austria) was immortalized by infecting primary microglial cell cultures with a v- raf/v-myc 
oncogene (Blasi et al., 1990). BV-2 cells were maintained at 37 °C under a 5 % CO2 humidified 
atmosphere in RPMI 1640 supplemented with 10 % fetal bovine serum (FBS), 2 mM glutamine, 100 
μg/ml streptomycin, 100 U/ml penicillin, HEPES, and 0.1 mM NEAA. The cells were cultured at a 
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 flask, and were passaged every 2–3 days using 0.25 % trypsin. This 
study used only cells between passages 5–15. Prior to initiating the experiments, cells were cultured in 
fresh Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum 1000 
mg/L glucose, 2 mM glutamine, 100 g/mL streptomycin, and 100 U/mL penicillin, HEPES, and 0.1 
mM NEAA. The following cell seeding numbers were used: 1 × 10
3
 cells/well in a 96-well plate for 
determination of IL-6 protein level and NF-κB localization; 5 × 105 cells/well in a 12-well plate for 
gene expression analysis by RT-PCR; 1.0 × 10
6
 cells/well in a 6-well plate for Western blot analysis. 
Total mRNA isolation and quantitative real-time PCR 
The mRNA expression of IL-6, iNOS, and GITR mRNA as well as GAPDH was determined by 
quantitative real-time PCR (RT-PCR). Briefly, total RNA from BV-2 cells was extracted with Tri-
reagent from Sigma Aldrich (St. Louis, MO, USA) according to the manufacturer’s protocol. The 
resulting RNA was dissolved in nuclease-free water (Invitrogen, Carlsbad, CA). The total RNA 
concentrations were measured using the NanoDrop ND-1000 (ThermoScientific, Wilmington, DE). 0.5 
g of total RNA was reverse transcribed to first strand complementary DNA (cDNA). The cDNA was 
synthesized using the Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA). cDNA was 
amplified by rotor-gene-3000A (Corbelt Research, Australia) using the KAPA SYBR
®
 FAST qPCR Kit 
(Kapasystems, Boston, MA). Each 10 μl reaction mixture consisted of 5 μl SYBR mater mix, 0.4 μl of 
each primer (5 μM), 2 μl of cDNA, and 2.2 μl RNase-free dH2O. Expression was normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Fold changes are reported relative to vehicle 
control. Fold changes were quantified as 2
-(ΔCt sample-ΔCt control)
, as described previously (Livak and 




Assay for IL-6 
The presence of immunoreactive IL-6 in cell culture supernatants was determined using mouse-specific 
ELISA for interleukin-6 (IL-6) from BD Biosciences (CA, USA) following the protocols provided by 
the manufacturer. The results were expressed in ng/ml.  
Determination of NF-κB localization by ArrayScan HCS Reader 
After treatment, the medium was discarded and cells were fixed and stained using Cellomics
®
NF-κB 
activation kit from Thermo Scientific according to the manufacturer's instructions. Brifly, cells were 
fixed with 4% formaldehyde (pH 7.2) at room temperature for 30 min, washed with PBS and then 
permeabilized with PBS containing 0.5% Triton X-100 for 10 min. After three washes with PBS and 
blocking with 1% fatty acid-free bovine serum albumin for 1 h the cells were incubated with rabbit 
polyclonal antibody against the p65 subunit of NF-κB (1:500) for 1 h at 37°C. Cells were then 
incubated with detergent buffer for 15 min and washed twice with PBS. Cells were then incubated with 
staining solution consisting of goat anti-rabbit IgG conjugated to Alexa Fluor 488 and Hoechst-33342 
for 1 h prior to a 10 min wash with detergent buffer and two washes with PBS. Cells were then soaked 
in PBS at 4°C and covered with aluminum foil until analysis by imaging. The assay plate was evaluated 
on ArrayScan HCS Reader. The Cytoplasm to Nucleus Translocation BioApplication software was used 
to calculate the ratio of cytoplasmic and nuclear NF-κB intensity (Ding et al., 1998). The average 
intensity of 500 objects (cells) per well was quantified. The ratios were then compared among treated 
and untreated cells. 
Preparation of whole cell lysates and cytoplasmic and nuclear fractions 
For whole cell lysate, the cells were harvested after the appropriate treatment and washed with ice-cold 
PBS for two times. Total cellular proteins were extracted by adding radio immunoprecipitation assay 
lysis buffer (RIPA buffer) (Sigma-Aldrich, St. Louis, MO) after addition of the protease inhibitor 
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cocktail (Roche Diagnostics, Mannheim, Germany). The lysate was centrifuged at 10,000 × g for 15 
min at 4°C.  
To separate the cytosolic proteins from the nuclear proteins, cells were collected by scraping in cold 
PBS. The cell pellet was then collected by centrifugation at 450 × g for 5 min, washed once with PBS 
and pelleted again at 1,000 × g for 5 min. The cell pellet was then lysed in hypotonic lysis buffer (100 
mM KCl, 15 mM MgCl2, 100 mM HEPES, pH 7.9) supplemented with 0.01 M DTT and protease 
inhibitors and kept on ice for 15 min. IGEPAL CA-630 solution (Sigma-Aldrich) (0.6% v/v final 
concentration) was then added to the cell suspension, followed by mixing for 10 s and centrifugation at 
10,000×g for 30 s. The supernatant was collected and designated the cytosolic fraction. Nuclear proteins 
were then extracted using a buffer containing 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 20 mM 
HEPES, pH 7.9, and 25% (v/v) glycerol) supplemented with 0.01 M DTT and protease inhibitor. The 
nuclear suspension was mixed thoroughly for 30 min and centrifuged at 12,000×g for 5 min. The 
supernatant, representing the nuclear fraction, was stored at −80°C. 
The protein concentration of the supernatant was measured with Pierce
®
 BCA protein assay kit (Thermo 
Scientific, US) according to the manufacturer's instructions. 
Detection of protein expression 
Equal amounts of protein samples (30 μg) were loaded onto 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and ran at 120 V for 2.5 h. Proteins were transferred 
to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA, US) for 1 h at 
120 mA on Bio-Rad Cells  (Bio-Rad Laboratories, Hercules, CA, US). The membranes were blocked 
with 5% nonfat milk in TBS-T (Tris-buffered saline with 0.1% Tween-20) for 1 h, washed, and then 
incubated with the primary antibody against p44/p42 MAPK (ERK1/2) (1:500), phospho-p44/p42 
MAPK (ERK1/2) (1:500), p38 MAPK (1:500), phospho-p38 MAPK (Thr180/Thr182) (1:500), 
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SAPK/JNK (1:1000), phospho-SAPK/JNK(Thr183/Tyr185) (1:1000), NF-B p65 (1:500), phospho-
NF-B p65 (1:500), GRP78 (1:500), HDAC1 (1:1000) or β-actin (1:1000) overnight at 4°C. The 
membranes were washed for ten times with 10 min with TBS-T and then incubated for 1 h with the 
horseradish peroxidase-conjugated secondary anti-IgG antibody using a dilution rate between 1:2000 
and 1:5000 in 5% nonfat milk in TBS-T. The membranes were further washed for ten times with 10 min 
in TBS-T. Immunoreactive bands were visualized with an enhanced chemiluminescence HRP substrate 
(Millipore, Billerica, MA, USA) for 2–5 min. Images were captured with a LAS-4000 luminescent 
image analyzer (Bucher Biotec, Basel, Switzerland). β-actin was used as loading control for cytoplasmic 
and whole cell protein extracts. HDAC1 was used as loading control for nuclear fractions. 
11β-HSD1 activity measurements in intact BV-2 cells 
11-HSD1 activity was measured by the conversion of radioactively labeled [3H]-cortisone to [3H]-
cortisol. After treatment, the medium was then removed and replaced by assay medium containing 50 
nM cortisone with 10 nCi 1,2-[
3
H]-cortisone at 37°C and 5% CO2 for 12 h in serum-free DMEM. The 
medium supernatant was collected. The supernatant was mixed with 2–3 volumes of ethyl-acetate by 
shaking and the lower hydrophilic and the upper lipophilic phases were separated by centrifugation. The 
upper steroid containing phase was fully evaporated, resolved with methanol containing a mixture of 2 
mM unlabeled cortisone and cortisol. Cortisone (E) and cortisol (F) separated by thin-layer 
chromatography using chloroform/methanol solvent system (9:1, v/v). [
3
H]-labeled cortisone and 





Statistical analysis of the data 
Data was expressed as mean ± SD from at least 3 independent experiments (n), each experiment with 
triplicate determinations. Data were analyzed with Prism software package version 5 from GraphPad, 
San Diego, CA. Data were subjected to one-way ANOVA and post hoc analysis. Differences were 
considered statistically significant at p < 0.05 and reported in each figure legend.  
 
RESULTS 
Increased production of inflammatory cytokines and receptors in BV-2 cells 
We investigated whether TMT could induce the expression of neuroinflammatory mediators in BV-2 
microglial cells. Several reports have recently indicated that TMT induced inflammatory response and 
reactive microglia marker expression in various cells (Fiedorowicz et al., 2008;Koda et al., 
2009;McPherson et al., 2011;Ravanan et al., 2011). Thus, we investigated the effects of TMT on the 
expression of inflammatory related genes in BV-2 cells, including IL-6, iNOS, inflammatory related 
receptor, and the glucocorticoid-induced tumor necrosis factor receptor (GITR). BV-2 cells were 
exposed to TMT at concentrations between 0.1-2 M for 24 h, showed a concentration dependent 
manner to increase in IL-6, iNOS, and GITR mRNA levels at 24 h (Fig. 1A). Similarly, a concentration-
dependent manner increase in the secretion of IL-6 induced by TMT was observed (Fig. 1B). The 
increase in IL-6 secretion correlates with an increase IL-6 mRNA expression.  
In order to investigate IL-6 expression over a time course following TMT exposure, cells were treated 
with either 1 M TMT or 10 ng/ml LPS for 0.25, 0.5, 1, 6, 12, 18, 24, and 48 h. The levels of secreted 
IL-6 were measured by ELISA. TMT induced a time-dependent increase in IL-6 protein (Fig. 1C). 
Exposure to 1 M TMT resulted in the elevation of IL-6 protein levels in the medium which reached 
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statistical significance at 1 h post-TMT exposure, and reached maxiumum expression at 18 h post-TMT 
treatment, the levels of IL-6 mRNA was reached the maximum, which declined thereafter (Fig. 1C). 
Levels of IL-6 protein within the control media mildly increased from baseline after 24 h.  
 
Activation of the NF-B signaling pathway by TMT in BV-2 cells 
Since NF-κB is well known to play a critical role in the expression of pro-inflammatory molecules, we 
investigated whether TMT activates NF-κB in microglial cells. The importance of TMT induced IL-6 
upregulation was investigated using the NF-B inhibitor Cay10512. Pretreatment with Cay10512 (250 
nM) for 1 h completely blocked TMT induced- IL-6 mRNA expression (Fig. 2A). 
To elucidate whether TMT activates the NF-B signaling pathway, we investigated the effect of TMT 
on NF-κB p65 subunit nuclear translocation in BV-2 cells. Cells were treated with 1 μM TMT for 24 h 
or pre-incubated with Cay10512 (250 nM) for 1 h prior to treatment with 1μM TMT for 24 h. The 
translocation of the NF-κB p65 subunit and the NF-κB p65 subunit protein expression was detected by 
CellomicsArrayScan high-content imaging analysis and Western blotting, respectively. TMT 
significantly induced the translocation of NF-κB p65 subunit from the cytosol into the nucleus (Fig. 
2B). This finding was confirmed by Western blot analysis of nuclear and cytosolic extracts (Fig. 2C). 
TMT treatment significantly increased NF-κB p65 subunit expression in nuclear extracts, which could 
be suppressed by pretreatment with Cay10512 (Fig. 2C). These results suggest that TMT induced the 
expression of neuroinflammatory molecules through the activation and nuclear translocation of NF-κB. 
Activation of the MAPKs signaling pathway by TMT in BV-2 cells 
Mitogen-activated protein kinases (MAPKs) play an important role in the activation of inflammatory 
genes, which may involve crosstalk between MAPKs and NF-κB pathway. We next examined whether 
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inhibitors of MAPKs had any effects of the TMT-induced up-regulation of IL-6 and iNOS mRNA 
expression in BV-2 cells. We used PD98059 (50 M), SB202190 (20 M) and SP600125 (20 M) that 
are selective inhibitors of ERK1/2, p38, and JNK, respectively. Pre-incubation of cells for 1 h with 
PD98059 or SB202190 prior to stimulation with 1 M TMT for 24 h reduced the TMT-upregulated 
mRNA expression of IL-6 and iNOS (Fig. 3A). In contrast, no significant effect on TMT-induced IL-6 
and iNOS expression was observed when cells were pretreated with SP600125. Similarly, treatment 
with any of three MAPK had no effect on the basal levels of IL-6 and iNOS mRNA expression. 
To further explore the relationship between TMT-induced IL-6 and iNOS mRNA expression and 
MAPK activation, we determined a time course for ERK1/2, JNK, and p38 activation in BV-2 cells 
following TMT stimulation. TMT-induced a time-dependent activation of ERK1/2 and p38 as 
determined by Western blot analysis for phospho-ERK (p42/p44) and phospho-p38. However, TMT did 
not affect JNK phosphorylation (Fig. 3B). The degree of ERK1/2 activation following 1 h stimulation 
with 1 μM TMT increased and continued to elevate until it reached a plateau at 2 h treatment (Fig. 3B). 
The phosphorylation of p38 induced by TMT was observed within 30 min of treatment (Fig. 3B). 
Additionally, cells were pre-treated with different MAPK inhibitors including PD98059 (ERK1/2 
inhibitor, 50 M,) and SB202190 (p38 inhibitor, 20 M), and SP600125 (JNK inhibitor, 20 M) for 1 h 
and then stimulated with TMT for 2 h. Interestingly, the phosphorylation of ERK1/2 induced by TMT 
was inhibited by PD98059 pretreatment but was potentiated by SB202190 and SP600125 pretreatment 
(data not shown). The phosphorylation of p38 induced by TMT was inhibited by all the MAPK 
inhibitors (data not shown). 
Cross-talk between MAPKs and the NF-B pathways has been reported in microglia cells (Wilms et al., 
2003;Gorina et al., 2011;Zheng et al., 2012). Therefore, the relationship between MAPKs and NF-κB in 
TMT induced inflammation was investigated. Cells were pre-treated with inhibitors for MAPKs for 1 h 
followed by TMT (1 M) treatment for 24 h. The expression of the NF-κB p65 subunit was confirmed 
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by Western blot analysis from nuclear and cytosolic extracts (Fig. 3C). Pretreatment with PD98059, 
SB202190, and SP600125 reversed the TMT-induced nuclear translocation of the NF-κB p65 subunit. 
Taken together, the data suggests that the effect of TMT on the induction of the inflammatory response 
is associated with the activation of ERK1/2 and p38 MAPKs pathways in BV-2 microglial cells. In 
addition, MAPKs may disturb the activation of NF-κB induced by TMT. 
Differential effect of RU-486 and spironolactone on the expression of pro-inflammatory mediators 
It has been demonstrated that corticosteroids such as corticosterone and dexamethasone disturb on 
MAPK and NF-κB activity (Auwardt et al., 1998;ten Hove et al., 2006;Armstrong et al., 2011;Manetsch 
et al., 2012;Mercado et al., 2012;Zhu et al., 2012) which result in an altered inflammatory response. 
Therefore, we want to investigate whether different glucocorticoids differentially influence TMT-
induced inflammatory responses. In the present study we used a specific GR agonist, dexamethasone. In 
addition, both active form corticosterone and inactive from dehydrocorticosterone of the unselective 
corticosteroid receptor agonist were used. Pretreating cells with dexamethasone (100 nM) for 1 h 
followed by TMT treatment for 24 h completely blocked TMT-induced IL-6 and iNOS mRNA 
expression (Fig. 4A). Similarly, dexamethasone pretreatment markedly suppressed the release of IL-6 
(Fig. 4C). Pretreating cells with either corticosterone (25 nM) or dehydrocorticosterone (50 nM) 
significantly enhanced TMT upregulation of IL-6 and iNOS mRNA expression and IL-6 secretion (Fig. 
4A and Fig 4C). 
To determine which receptor is involved in TMT induced inflammation in BV2 microglia cells, nuclear 
receptor blockers RU-486, a GR antagonist, and spironolactone, a MR antagonist were tested. 
Pretreatment with 1 μM spironolactone completely abolished the effect of TMT on IL-6 and iNOS 
mRNA expression (Fig. 4B). In contrast, pretreatment with RU-486 (1 μM) enhanced the action of 
TMT (Fig. 4B). Interestingly, the secretion of IL-6 stimulated by TMT was partially blocked by 
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spironolactone (Fig. 4D). These results suggest that the stimulatory effect of TMT on inflammation 
involves the MR. 
MAPKs and NF-κB activity are differentially modulated by different steroid receptors including MR 
and GR (Auwardt et al., 1998;Fu et al., 2012;Zhu et al., 2012;Long et al., 2013). To further investigate 
which receptors modulatethe potentiating effect of corticosterone on TMT actions, RU-486 and 
spironolactone were used. Pretreatment with 1 μM spironolactone completely antagonized the 
stimulatory effect of 25 nM corticosterone to increase IL-6 expression but not RU-486 (Fig 4B and 4D).   
The potentiation of TMT induced inflammation by corticosterone on TMT acts through MAPKs 
Reports show glucocorticoid reamplification reinforces the inflammatory response was reported, this 
process is associated with MAPKs and 11β-HSD1 activity (Hu et al., 2009;Ishii-Yonemoto et al., 
2010;Ahasan et al., 2012). Our studies found that 11β-HSD1 mediated the potentiation of the 
inflammatory action of corticosterone. Moreover, corticosterone also activated MAPKs (Nguyen Dinh 
Cat et al., 2011;Komatsuzaki et al., 2012). Therefore, we investigated the involvement of MAPKs on 
the potentiation of TMT-induced inflammation by corticosterone by measuring IL-6 mRNA expression 
and IL-6 release. 
Preincubation of cells for 1 h with PD98059 or SB202190 prior to stimulation with 1 M TMT for 24 h 
reduced the TMT-upregulated mRNA expression of IL-6 and iNOS (data not shown). In contrast, no 
significant effect on the TMT-induced expression of IL-6 and iNOS was observed when cells were 
pretreated with SP600125. Similarly, treatment with any of three MAPK inhibitors did not affect the 
basal levels of IL-6 and iNOS mRNA expression. These results suggest that potentiation effect of 
corticostrone on TMT-induced inflammation is mediated by ERK1/2 and JNK. 
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TMT induces inflammation by modulating 11-HSD1 
It has been demonstrated that 11-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enhanced 
inflammation through local glucocorticoid activation (Hardy et al., 2006;Hardy et al., 2008;Kaur et al., 
2010). 11β-HSD1 converts inactive steroids (such as cortisone and 11-dehydrocorticosterone) to their 
active counterparts (cortisol and corticosterone) (Tomlinson et al., 2004;Cooper and Stewart, 2009). 
According to the potentiation effect of corticosterone and 11-dehydrocorticosterone on TMT-induced 
inflammation, we hypothesized that the stimulatory effect of glucocorticoids on the inflammatory 
responses-induced by TMT is mediated by local glucocorticoid activation through 11β-HSD1.  
Pretreatment with BNW-16, an 11β-HSD1 inhibitor, completely abolished the effect of 11-
dehydrocorticosterone on TMT-induced IL-6 mRNA expression. Additionally, the stimulatory effect of 
corticosterone was also partially blocked by BNW-16 pretreatment. Similar results were obtained 
monitoring the levels of IL-6 release (data not shown). 
TMT induced 11-HSD1 function 
We observed that the TMT induced inflammatory response in BV-2 cells was mediated through NF-κB, 
ERK1/2, p38 and MR. The potentiation effect of corticosterone and 11-dehydrocorticosterone on 
inflammation induced by TMT was reversed by an 11β-HSD1 inhibitor. Recently, several studies have 
shown that 11β-HSD1 expression is upregulated by NF-κB and ERK1/2 (Frey et al., 2004;Hu et al., 
2009;Ishii-Yonemoto et al., 2010;Chantong et al., 2012;Lee et al., 2013). Therefore, we hypothesized 
that TMT may regulate the levels of 11-HSD1. We investigated the direct effect of TMT on 11-
HSD1 mRNA and activity. Treatment with TMT for 24 h induced 11-HSD1 mRNA expression and 
11-HSD1 activity in concentration-dependent manner (Fig 5A, 5B). 
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Pathways involving the induction of 11-HSD1 by TMT 
To investigate the pathways involved in TMT induced upregulation of 11-HSD1, we measured 11-
HSD1 mRNA induced by TMT following pretreatment of cells with specific inhibitors or antagonists 
for NF-κB, ERK1/2, p38, JNK, GR and MR with Cay10512, PD98059, SB203580, SP600125, RU486 
and spironolactone, respectively. As shown in Fig. 6A, pretreatment cells with Cay10512 completely 
blocked TMT induced 11-HSD1 expression. PD98059, SB203580, RU486 and spironolactone 
significantly blocked TMT-induced 11-HSD1 expression. However, SP600125 had no effect. These 
results suggest that TMT induced 11-HSD1 mRNA through NF-κB, ERK1/2, p38, MR and GR. 
We found corticosterone potentiated the inflammatory response of TMT. Therefore, we investigated the 
action of corticosterone on TMT-induced 11-HSD1 mRNA expression. Cells were pretreated with 
specific inhibitors or antagonists of NF-κB, ERK1/2, p38, JNK, GR and MR with Cay10512, PD98059, 
SB203580, SP600125, RU486 and spironolactone respectively and then stimulated with corticosterone 
and TMT. As shown in Fig. 6B, pretreatment cells with Cay10512, PD98059, SB203580, RU486, and 
spironolactone significantly blocked the TMT-induced 11-HSD1. However, SP600125 had no effects. 
These results suggest that potentiation effect of corticosterone on TMT induced 11-HSD1 mRNA is 
mediated by ERK1/2, p38, MR, and GR. 
 
DISCUSSION 
In this study, we have demonstrated that TMT, at low concentrations, stimulates a concentration-
dependent up-regulation of inflammatory related genes including IL-6, iNOS, and GITR in mouse 
microglial cells (Fig. 1A). The release of IL-6 stimulated by TMT was concentration- and time-
dependent (Fig. 1C and Fig. 1D). TMT intoxication has been suggested to play a role in microglia 
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activation and subsequent neuroinflammation neuroinflammation (Pompili et al., 2004;Koda et al., 
2009). Microglia surrounding neurons were targeted by TMT and resulted in up-regulation of pro-
inflammatory cytokines. It has been suggested that microglia are directly involved in TMT induced 
neurotoxicity (Geloso et al., 2011;Huong et al., 2011;Yang et al., 2012). The molecular mechanism of 
TMT induced inflammation in microglia is still not well-established. TMT induced cytotoxicity with an 
increase protease-activated receptor-1 (PAR-1) in rat primary microglia cells at the concentration of 10 
µM after 48 h exposure (Pompili et al., 2011). In human microglia cell cultures, TMT at concentration 
of 5 x 10-3 nM increased iNOS and TNF- expression 1.5 and 2.5 fold, respectively, compared with 
control (Reali et al., 2005). However, our study showed that 0.1 M TMT could induce the expression 
of IL-6, iNOS and GITR mRNA with 1.25, 3.12, and 4.01 fold, respectively, in mouse microglia cells. 
This indicates that human microglia cells are more susceptibility to TMT toxicity than rodents. In 
addition to cytokine expression, GITR has been reported to play an important role in inflammatory 
diseases. GITR contributes to the in vivo development of the inflammatory response as well as the in 
vitro enhancement of dendritic cell activity (Ronchetti et al., 2011).   
Activated NF-κB enters the nucleus and promotes the transcription of its target genes, including the pro-
inflammatory cytokine IL-6 and iNOS (Cheng et al., 2009;Xu et al., 2011;Lukiw, 2012). An increase in 
IL-6 secretion was prevented by pretreating cells with Cay10512, an NF-B inhibitor (Fig. 2A). An 
increase in nuclear translocation and protein levels of the NF-B p65 subunit in nucleus was induced by 
TMT (Fig. 2B, 2C). These results are consistent with a previous observation showing that TMT at 5 M 
significantly increased translocation of NF-κB p65 subunit into nucleus in human neuroblastoma cells 
SY5Y. However, NF-κB inhibitors, MG132 and BAY11-7082, promoted TMT-induced cytotoxicity  
and early apoptosis (Qing et al., 2013). Bay 117082, a NF-B inhibitor blocked the up-regulation of 
iNOS mRNA induced by TMT in human microglia cells (Reali et al., 2005). 
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MAPK kinases (ERK1/2, JNK and p38 MAPK) play important roles in mediating inflammatory 
responses in microglia cells through the relaying extracellular signals to various intracellular pathways 
and regulating stress-induced neurodegeneration (Katsuki et al., 2006;Choi et al., 2009;Wang et al., 
2011b). We found that inhibitors of ERK and p38-MAPK significantly reduced the TMT-induced 
mRNA expression of IL-6 and iNOS (Fig. 3A). Immunoblotting analysis revealed that ERK1/2 and p38 
but not JNK are intimately involved in the TMT stimulated mRNA expression of IL-6 and iNOS 
microglia (Figure 3A-3C). The earliest time point for TMT stimulation of ERK and p38 MAPK 
activation was 1 and 0.5 h, respectively (Fig. 3B). TMT activation of the ERK, p38, and JNK pathways 
was observed in primary cultures of cerebellar granule cells but only JNK and p38 inhibitors were able 
to protect TMT-induced apoptosis (Mundy and Freudenrich, 2006). Neuronal damage induced by TMT 
was dependent on the JNK cascades in primary cultures of cortical neurons which JNK inhibitor 
partially attenuated the TMT-induced nuclear condensation and accumulation of lactate dehydrogenase 
(Shuto et al., 2009b). In human neuroblastoma cells, an increase in the phosphorylation of ERK, p38, 
and JNK was observed during the 24-h exposure of TMT and pretreatment with ERK1/2 and JNK 
inhibitor reduced in TMT-induced cytotoxicity (Qing et al., 2013). TMT induced apoptosis via caspase 
activation, p38, and oxidative stress in PC12 cells (Jenkins and Barone, 2004). Our study showed the 
first evidence of the role of MAPKs pathways in the regulation of TMT-induced proinflammatory 
mediators in microglia cells. 
An increasing amount of evidences in vivo implicates the role of corticosteroids including 
corticosterone and dexamethasone in TMT-induced toxicity and inflammation. For instance, treatment 
with dexamethasone almost prevented TMT-induced neuronal damage and behavioral abnormalities by 
attenuating oxidative stress (Shuto et al., 2009a). Both high and low levels of circulating corticosterone 
altered the rate of neuropathological and behavioral changes induced by TMT in rats (Tsutsumi et al., 
2002). Corticosterone and dexamethasone administration partially reversed TMT-induced enhancement 
of IL-1 and IL-6 expressions in the reactive gliosis (Liu et al., 2005). Treatment with dexamethasone 
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prior to TMT potentiated the action of TMT on the elevation of TNF-, TNF-, and IL-1 levels in rat 
hippocampus (Bruccoleri et al., 1999). Prolonged administration of corticosterone or dexamethasone but 
not aldosterone partially reversed the TMT-induced neuronal loss and reactive astrocytosis. (Imai et al., 
2001). Furthermore, corticosteroids disturb the NF-B and MAPKs pathways resulting in a change in 
cytokine release. (Auwardt et al., 1998;ten Hove et al., 2006;Armstrong et al., 2011;Manetsch et al., 
2012;Mercado et al., 2012;Zhu et al., 2012). In the present study, corticosterone (25 nM) and inactive 
form, 11-dehydrocorticosterone (50 nM) potentiated TMT-induced IL-6 and iNOS mRNA expression as 
well as IL-6 release (Fig. 4A and 4C). A MR antagonist, spironolactone, blocked the action of TMT. On 
the contrary, a GR antagonist, RU486 enhanced TMT-induced cytokine expression (Fig. 4B and 4D). 
This result is consistent with previous evidences in animal studies indicating that neuronal 
degeneration-induced by TMT was prevented by dexamethasone treatment but was exacerbated by 
mifepristone, a GR antagonist (Shuto et al., 2009b). Neurotoxicity induced by TMT in the mouse 
hippocampus was enhanced by aldosterone which was reversed by spironolactone (Ogita et al., 2012). 
MR has been proposed to play a role in microglia activation and promotion of inflammation in brain 
during cerebral ischemia (Guo et al., 2008). The inhibitory effect on MKP-1-dependent MAPK 
pathways was induced by dexamethasone in activated microglia (Huo et al., 2011). The absence of GR 
in microglia induced the prolongation of NF-κB transcriptional activity and led to its persistent 
activation (Ros-Bernal et al., 2011).  
Interestingly, the potentiation effect of corticosterone on TMT-induced cytokine expression was 
reversed by spironolactone but potentiated by RU486 (Fig. 4B and 4D). This result indicates that MR 
plays a role in corticosterone action. Corticosteone has a 10-fold higher affinity for the MR than the GR 
(De Kloet et al., 1984). Several studies have been shown that an increase in MAPKs phosphorylation 
was induced by corticosterone. For example, a release of corticosterone after stress leads to an 
activation of p38 and the p42/44 MAP kinases (Ahmed et al., 2006). Stress induced elevation of 
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corticosterone levels has been associated with MAPKs activation in rat hippocampus (Moosavi et al., 
2011). The role of MR on MAPKs activation has also been investigated. Adosterone activated MAPKs 
resulted in ROS production which induced renal toxicity. The effects were reversed by a MR antagonist 
(Kiyomoto et al., 2008). An induction of adipocyte-derived factor mediated by MAPK activation in 
adipocytes was attenuated by MR antagonist (Nguyen Dinh Cat et al., 2011). However, no direct 
evidence indicating the involvement of MR on activation of MAPKs induced by corticosterone was 
reported. In the present study, the potentiation effect of corticosterone on TMT-induced IL-6 and iNOS 
mRNA expression was inhibited by inhibitors for ERK1/2 and p38. 
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an intracellular enzyme that acts primarily as 
a reductase to convert inactive glucocorticoids into active form in tissues. It thus potentiates local 
glucocorticoid activity (Tomlinson et al., 2004;Cooper and Stewart, 2009). This enzyme has been 
suggested to increase inflammation (Hardy et al., 2006;Hardy et al., 2008;Kaur et al., 2010). The 
potentiation effect of 11-dehydrocorticosterone on TMT-induced cytokine expression was completely 
block by 11β-HSD1 inhibitor. Additionally, 11β-HSD1 inhibitor also blocked the stimulatory action of 
active corticosterone. These results indicate that the local concentration of corticosterone mediated by 
11β-HSD1 may contribute to TMT action. Induction of 11β-HSD1 mRNA expression and 11β-HSD1 
activity by TMT was observed in a concentration dependent manner (Fig. 5A, 5B). Several evidences 
have shown that TMT increased plasma corticosterone (Tsutsumi et al., 2002;Liu et al., 2005;Shirakawa 
et al., 2007;Little et al., 2012;Ogita et al., 2012). However, the role of TMT on local glucocorticoid 
regulation has not been reported. Our results suggest that TMT may disturb endogenous locally active 
corticosterone levels by increase of 11β-HSD1 mRNA expression and 11β-HSD1 activity. 
11β-HSD1 is positively modulated by MR, NF-κB and ERK1/2 (Frey et al., 2004;Hu et al., 2009;Ishii-
Yonemoto et al., 2010;Chantong et al., 2012;Lee et al., 2013) which are coinsidently the same pathways 
disturbed by TMT in microglia cells. In the present study, Cay10512, a NF-B inhibitor, completely 
abolished TMT-induced 11β-HSD1 mRNA expression. Inhibitors for ERK1/2, JNK, GR, and MR 
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attenuated the action of TMT on 11β-HSD1 expression (Fig. 6A). These results confirm that the action 
of TMT on stimulation of inflammation may be related to 11β-HSD1. Furthermore, corticosterone also 
potentiated 11β-HSD1 expression induced by TMT. As expected, pretreating cells with inhibitors of 
NF-B, ERK1/2, JNK, GR, and MR blocked the potentiation effect of corticosterone on TMT-induced 
11β-HSD1 expression. Therefore, the inflammatory action of TMT might be related to 11β-HSD1 level 
and activity and local glucocorticoid concentrations. TMT induced 11β-HSD1expression was mediated 
by NF-B, ERK1/2, JNK, which are the same pathways which induce TMT regulated inflammation. 
However, there are differences in receptor regulation in the two pathways. Both MR and GR positively 
mediated TMT-induced 11β-HSD1expression but TMT induced inflammation was mediated by the MR 
only. Classically glucocorticoids prevent inflammation but they act together with the pro-inflammatory 
cytokines to synergistically increase 11-HSD1 expression in a variety of cell types (Sun and Myatt, 
2003;Kaur et al., 2010). Inhibition of 11β-HSD1 emerges as a promising approach for the treatment of 
inflammatory-related diseases (Walker, 2006;Sun et al., 2011;Wang et al., 2011a). Furthermore, down-
regulation of genes that play a role in humoral defense mechanisms, acute-phase response, and immune 
response was observed in mice treated with an 11β-HSD1 inhibitor (Luo et al., 2013). 
In summary, microglia exposed to TMT (Fig. 7), in combination with glucocorticoids, including 11-
dehydrococrticosterone and corticosterone, respond by enhancing the expression of proinflammatiory 
cytokines and iNOS. The potentiation effects are regulated by local glucocorticoid levels which are 
balanced through NF-B, ERK1/2, and JNK regulation. The MR is suggested to play a role in both 
controlling the action of TMT, and the stimulatory effect of glucocorticoid on the inflammatory 
response. The role of brain microlgia in the mechanism of TMT induced neurotoxicity, especially 
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Figures and Figure Legend 
 
 
Fig.1. TMT stimulated inflammatory response in BV-2 cells. (A) Concentration dependent effect of 
TMT on IL-6, iNOS, and GITR mRNA expression. Cells were treated with TMT at the concentrations 
range 0.1-2 M. The mRNA levels were quantified and normalized to the level of GAPDH by real-time 
RT-PCR analysis. (B) Concentration dependence of TMT on IL-6 release. Cells were treated with TMT 
at the concentrations range of 0.1-2 M. Levels of IL-6 in the culture medium of BV-2 treated cells 
were detected by ELISA. (C) Time course for TMT-stimulated IL-6 release. Levels of IL-6 in the 
culture medium of BV-2 cells treated with either 1 M TMT or 10 ng/ml LPS were detected by ELISA. 
Results were expressed as the mean ± SD of at least 3 independent experiments and significant was 
determined by one-way ANOVA followed by Turkey’s tests, *p < 0.05, **p < 0.01; ***p < 0.005. 
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 Fig. 2. NF-κB is involved in the induction of IL-6 by TMT. Cells were treated with TMT (1 M) or 
0.1% DMSO for 24 h after pre-incubation without or with 250 nM Cay10512 for 1 h. (A) IL-6 mRNA 
levels were measured by RT-PCR and were quantified and normalized to the level of GAPDH. (B) 
Analysis of the intracellular localization of the p65subunit of NF-κB by Cellomics ArrayScan HCS 
imaging system. The ratio between the intensity of nuclear p65 fluorescence and total cellular p65 
fluorescence was quantitated. (C) Western blot analysis using antibodies against phospho-p65 and p65 
subunit of NF-κB in nuclear and cytoplasmic fractions. Representative blots from 3 independent 
experiments. Results were expressed as the mean ± SD of at least 3 independent experiments and 




Fig 3. Activation of the MAPKs signaling pathway by TMT in BV-2 cells. (A) The effects of MAPK 
inhibitors on TMT-induced IL-6 and iNOS mRNA expression. Cells were pre-treated with specific 
MAPK inhibitors (PD98059 for ERK1/2, SP600125 for JNK, and SB203580 for p38) at the 
concentrations of 50, 20 and 20 M respectively, for 1 h and then stimulated with TMT (1 μM) for 24 h. 
mRNA levels were measured by RT-PCR and were quantified and normalized to the level of GAPDH. 
(B) Time course of the effect of TMT on the phosphorylation of MAPKs. BV-2 cells were treated with 
TMT (1 M) for 0.5, 1, and 2 h. (D) MAPKs inhibitors and the effect on TMT-induced p65 
phosphorylation. Cells were pre-treated with specific MAPK inhibitors for 1 h and then stimulated with 
TMT (1 μM) for 24 h. Western blot analysis using antibodies against phospho-p65 and p65 subunit of 
NF-κB in nuclear and cytoplasmic fractions. Representative blots from 3 independent experiments. 
Results were expressed as the mean ± SD of at least 3 independent experiments and significance was 
determined by one-way ANOVA followed by Turkey’s tests, *p < 0.05, **p < 0.01; ***p < 0.005. 
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 Fig. 4. The effect of GR and MR antagonists on TMT-induced inflammatory responses. Cells were pre-
treated with corticosterone, dehydrocorticosterone and dexamethasone at the concentrations of 25, 50, 
and 100 nM respectively for 24 h and then stimulated with TMT (1 μM) for 24 h. (A) IL-6 and iNOS 
mRNA levels were measured by RT-PCR and were quantified and normalized to the level of GAPDH. 
(C) The levels of IL-6 in the culture medium were detected by ELISA. Cells were pre-treated with 
RU486 (1 μM) and spironolactone (1 μM) for 1 h, followed by incubation with 25 nM corticosterone 
for 24 h and continued stimulating with 1 M TMT for 24 h. (B) IL-6 and iNOS mRNA levels were 
measured by RT-PCR and were quantified and normalized to the level of GAPDH. (D) The levels of IL-
6 in the culture medium were detected by ELISA. Results were expressed as the mean ± SD of at least 3 
independent experiments and significance was determined by one-way ANOVA followed by Turkey’s 
tests, *p < 0.05, **p < 0.01; ***p < 0.005. 
176 
  
Fig. 5. TMT induced 11-HSD1 in concentration dependent manner. (A) TMT induced 11-HSD1 
mRNA expression. Cells were treated with TMT at the concentration range 0.1-2 M for 24 h. 11-
HSD1 mRNA levels were quantified and normalized to the level of GAPDH by real-time RT-PCR 
analysis. (B) TMT induced 11-HSD1 activity. Cells were treated with TMT at the concentrations range 
0.5-2 M for 24 h. 11-HSD1 activity was determined by the conversion of cortisone to cortisol. 
Results were expressed as the mean ± SD of at least 3 independent experiments and significance was 





Fig. 6. TMT induction of 11-HSD1 is mediated through NF-κB, ERK1/2, p38, and MR. (A) Cells 
were pre-treated with Cay10512 (250 nM), PD98059 (50 M), SP600125 (50 M), SB203580 (20 M), 
RU486 (1 μM) and spironolactone (1 μM) for 1 h and then stimulated with TMT (1 μM) for 24 h. (B) 
Cells were pre-treated with Cay10512 (250 nM), PD98059 (50 M), SP600125 (50 M), SB203580 (20 
M), RU486 (1 μM) and spironolactone (1 μM) for 1 h and followed by incubation with 25 nM 
corticosterone 24 h and continued stimulating with 1 M TMT for 24 h. 11-HSD1 mRNA levels were 
measured by RT-PCR and were quantified and normalized to the level of GAPDH. Results were 
expressed as the mean ± SD of at least 3 independent experiments and significance was determined by 




Fig. 7 Proposed model of the inflammatory mechanism of trimethyltin (TMT) in BV-2 cells. This 
study suggests that TMT activates MR which activates ERK1/2, p38 MAPKs, and NF-B to increase 
IL-6 and iNOS expression. Corticosterone potentiates the action of TMT by stimulating the same 
receptor, MR. TMT directly activates 11-HSD1 activity. An up-regulation of 11-HSD1 mRNA is 
also induced by TMT through MR-mediated pathway. Activation of GR by dexamethasone or high 
concentration of corticosterone suppresses MAPKs and inflammation but increased 11-HSD1 mRNA 







Conclusion and outlook 
Neuroinflammation is an important contribution to neurodegenerative diseases such as Alzheimer's 
disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis. Microglia activation results 
in an increased expression of cytokines and ultimately leads to oxidative and ER stress that cause 
neuronal damage and neurodegenerative diseases (4,12,100,204,205). Among the mechanisms involved 
our research focused on microglia activation and observe the cellular and molecular inflammatory 
signaling that leads to oxidative stress and ER stress. Activated microglia become highly pro-
inflammatory cells through their production of cytokines, chemokines and free radicals. 
Corticosteroids regulate the function of microglia through mineralocorticoid receptors (MR) and 
glucocorticoid receptors (GR) (41,50,52). The function of MR in microglia cells is suggested to increase 
microglia activity (46,50). In contrast, the GR exerts inhibitory effects (51,52). Although corticosteroids 
including corticosterone have a potent anti-inflammatory effects at pharmacological concentrations 
(31,57-59), many studies have shown that corticosterone also has a proinflammatory potential in 
microglia (29-31,34). Based on our observations (Figure 2), we propose that activation of MR results in 
an increased cytokine expression and release. MR activation stimulates the NF-B pathway. In contrast, 
activation of GR inhibits NF-B activity, resulting in suppression of inflammation. 11β-hydroxysteroid 
dehydrogenase 1 (11β-HSD1) modulates local glucocorticoid availability by converting inactive to 
active glucocorticoids. Corticosterone at low concentrations acts through MR to activate NF-B and 
stimulates production of proinflammatory cytokines such as IL-6 and TNF-. At high concentrations, 
corticosterone binds to GR to inhibit NF-B and proinflammatory mediators. Pro-inflammatory 
cytokines, like IL-6 and TNF- induce 11-HSD1 expression. This leads to increased active 
glucocorticoid concentrations resulting in the activation of GR and suppression of NF-B. Thus a 
precise control of the balance of MR and GR activity is essential for the resolution of inflammation. 
Additional to corticosteroid receptors, microglia function is also regulated by metabotropic glutamate 
receptors (mGluRs), which have eight subtypes based on their signal transduction pathways and 
pharmacological profiles (67,69). Metabotropic glutamate receptor subtype 5 (mGluR5) mediates their 
signaling through Gαq-proteins which activate PLC, leading to phosphoinositide hydrolysis and 
intracellular Ca
2+
 mobilization and also activation of ERK1 and ERK2 downstream signaling pathways 
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(67). mGluR5 is expressed in microglia (66,70) and activation of mGluR5 inhibits microglia activation, 
oxidative stress, and the release of inflammatory mediators both in vitro and in vivo (71-76). The 
present study indicates that antagonism of mGluR5 by MPEP results in an elevation of [Ca
2+
]i from the 
ER, probably through IP3 receptor activation, leading to induction of ER stress, oxidative stress and 
inflammation in microglia cells (Figure 3). The results propose that mGluR5 has at least two 
independent pathways to regulate the stress and inflammatory responses. First, mGluR5 may suppress 
Gi/ pathway resulting in a decrease in PLC activity and Ca2+ release from the ER. However, mGluR5 
has been documented to activate the Gαq-protein leading to activation of PLC, PKC and Ca2+ release 
(72). Therefore, it could be postulated that mGluR5 may cross-regulate Gi-couple receptors or mGluR5 
has a direct modulatory effect on Gi (PTX-sensitive protein) protein so it needs further investigation. 
Second, mGluR5 may regulate the AMPK pathway that influences mitochondrial function. Inhibition of 
mGluR5 results in ATP depletion which was reversed by AMPK activation. Decreased ATP production 
leads to not only an increased ROS production in mitochondria and oxidative stress but also an 
activation of AMPK to maintain energy homeostasis. Prolonged AMPK activation can induce ER stress. 
We propose suggest a model of a direct effect of mGluR5 antagonism in microglia on oxidative stress, 
inflammation and ER stress mediated by Ca
2+
 homeostasis. In addition, AMPK is also involved in 
mGluR5 receptor regulation. 
Chronic exposure or acute exposure of xenobiotics such as organotin compounds causes a progressive 
neurodegenerative disorder (194,198,206). However, the mechanisms of organotin action in microglia 
have not been well characterized. In the present studies, we focused on two structurally different 
organotins. DBT is a diorganotins found in the environment and in dietary sources (175-177,179). It has 
been shown to be a neurotoxicin various models (179,194-197). In the present studies, we investigated 
the signaling involved in DBT-induced microglia dysfunctions, including inflammatory response and 
oxidative stress (Figure 4). DBT increased cytokine expression and release such as IL-6 and TNF- 
through NF-B activation. Oxidative stress was induced by DBT, which is suggested to be mediated by 
NOX-2, AMPK and Ca
+2
 dysregulation. The results indicate that MAPKs may play a role in DBT-
induced inflammation but it remains unclear whether DBT directly affects on MAPKs or whether it acts 
through PKC and PLC. PI3K/Akt pathway is suggested to be involved in DBT action on inflammation. 
Ca
+2
 seems to be a central regulator of DBT action because BAPTA-AM could completely block the 
action of DBT on inflammatory response and oxidative stress.  
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TMT is an organotin compound with potent neurotoxic effects characterized by neuroinflammation and 
microglia activation (167,169,207,208). TMT also disturbed the balance of endogenous corticosterone 
regulation, resulting in enhanced neurotoxicity (170-173). Although TMT neurotoxicity is generally 
well documented there are few studies on disturbance of endogenous corticosteroids in microglia cells. 
In the present studies, TMT increased inflammation with activation of iNOS and IL-6 (Figure 5). The 
activation of MR is proposed to be the target of TMT action that activates ERK1/2, p38 MAPKs, 
followed by NF-B activation. Corticosterone binds to MR and potentiates the action of TMT on 
inflammation. TMT disturbs local availability of corticosterone by activation of 11-HSD1 activity and 
expression. When the concentration of corticosterone exceeds the affinity of GR for this hormone, it 
leads to inhibition of MAPKs and inflammation. These results partly explain the increased severity of 
TMT neurotoxicity during stress. 
Collectively, the present research contributes to the understanding that  
1. GR and MR activity differentially regulate inflammatory response in microglia cells. Feed-
forward and feedback regulation between MR and GR is adjusted by 11β-HSD1 to maintain 
cellular homeostasis. 
2. Factors influencing 11β-HSD1 such as stress, infection, and xenobiotic compounds affect the 
susceptibility of microglia cell activity and neuroinflammation. 
3. Metabotropic glutamate receptor 5 (mGluR5) has protective effects on microglia by 
modulating calcium-mediated pathways and AMPK-mediated pathways. 
4. Xenobiotics such as silane, DBT and TMT activate microglia and increase inflammation by 




Figure 2 : Model for the role of MR and GR in regulating neuroinflammation in BV-2 cells. This study 
suggests that MR promotes a neuroinflammatory response mediated through NF-κB activation, which 
can be blocked by activation GR. The control of local glucocorticoid availability by 11β-HSD1 is 
important in regulating the fine-tuning of the balance between MR and GR activity. Corticosterone 
binds with high affinity to MR, followed by binding to GR with lower affinity. 11β-HSD1 inhibitors 
(such as T0504) block the differential effects of 11-dehydrocorticosterone on MR and GR. IL-6 
stimulated 11β-HSD1 expression, suggesting that IL-6 is involved in a regulatory feed-forward 
mechanism to adjust the local levels of active glucocorticoids and therefore the balance between MR 
and GR. IL-6 and TNFR2 activation both lead to the activation of NF-κB, and their own expression is 
upregulated upon NF-κB activation. 
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Figure 3 : Proposed model of signaling pathway of mGluR5 regulation in BV-2 cells. Our results 
suggest that blockage of mGluR5 may activate PTX-sensitive G-protein (Gi-protein) leading to 
increased IP3 through PLC activation. An increased Ca
2+
 release from the ER induces ER stress, 
oxidative stress and inflammatory response of the cell. mGluR5 may also directly modulate AMPK, 
which contributes to the maintainance of mitochondrial functions. Disturbance of energy homeostasis 
induces AMPK activation and prolonged ATP depletion and elevated calcium can cause ER stress. 
184 
  
Figure 4 : Model of the inflammatory mechanism of dibutyltin (DBT) in BV-2 cells. This study 
suggests that DBT increases inflammation via activation of MAPKs, which is mediated by PLC and 
PKC. DBT activates NF-B activity, leading to enhanced inflammation, which may be regulated by 
Ca
2+
. DBT induced mitochondrial dysfunction, resulting in a decrease ATP production and increased 
oxidative stress through AMPK pathway. An induction of oxidative stress by DBT promotes the 
inflammatory response involving NOX-2. The loss of calcium homeostasis is postulated to be a main 






Figure 5 : Model of the inflammatory mechanism of trimethyltin (TMT) in BV-2 cells. This study 
suggests that TMT activates MR that activates ERK1/2, p38 MAPKs, and NF-B to increase IL-6 and 
iNOS expression. Corticosterone potentiates the action of TMT by stimulating the same receptor, MR. 
TMT directly activates 11-HSD1 activity. An up-regulation of 11-HSD1 mRNA also is induced by 
TMT through MR-mediated pathway. Activation of GR by dexamethasone or high concentration of 
corticosterone suppresses MAPKs and inflammation but increased 11-HSD1 mRNA leading to 
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